Annual Meeting
The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Washington, D.C., from April 20–24, 1996. The Chairperson of the Annual Meeting is Lorraine J. Gudas of the Cornell University Medical College. Dr. Gudas and her Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, methods workshops, controversy sessions, and meet-the-expert sunrise sessions. The Committee will also review proffered papers for scheduling in minisymposia, poster discussion sessions, and poster sessions. The deadline for abstract submissions is December 1, 1995.

Gertrude Elion Cancer Research Award
Applications for the AACR’s 1996 Gertrude Elion Cancer Research Award, supported by an educational grant from Glaxo Wellcome Oncology, are due February 15, 1996. The one-year, $30,000 grant to a nontenured Assistant Professor supports meritorious basic, clinical, or translational research in cancer causation, prevention, or treatment. Tenured faculty in academia, government employees, and employees of private industry are not eligible for this award. Information and application forms were mailed to AACR members and those who have requested applications. Nonmembers should request information and applications from the AACR office.

New Research Fellowships Available
This year the AACR will offer two new one-year, $30,000 grants to clinical or postdoctoral fellows. A research award for a postdoctoral/clinical fellow in clinical/translational research will be sponsored by Amgen. A research award for postdoctoral fellows in basic research will also be available. To be eligible for either fellowship, candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. All AACR members will receive information and an application form by mail in the near future. Nonmembers may request information and forms from the AACR office. The deadline for applications for the new research fellowships is February 15, 1996.

Travel Grants from the Comprehensive Minority Biomedical Program of the National Cancer Institute
Funds are being provided through the Comprehensive Minority Biomedical Program of the National Cancer Institute for the travel of a limited number of minority students to the 1996 AACR Annual Meeting. Eligible scientists are young, full-time predoctoral students, postdoctoral fellows, and physicians in training who are engaged in cancer research or who have training that could lead to contributions in this field. This travel program applies only to minority groups that have been defined by the National Cancer Institute as being traditionally underrepresented in cancer research; these groups are American Indians, Blacks, Hispanics, Native Alaskans, and Native Pacific Islanders. Only citizens of the United States and Canada or scientists who are permanent residents in those countries may receive one of these awards.

Although preference will be shown to authors of abstracts that have been accepted for presentation at the Annual Meeting, this is not a requirement for the award. Awardees will be selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees. An advisory committee consisting of members of the AACR will review submitted applications and letters of reference. The award will consist of partial support of registration, travel, and subsistence expenses incurred in connection with attendance at the Annual Meeting.

Applicants will be chosen from minority institutions as well as the larger bodies of universities, colleges, and research institutes. Travel grants are awarded to the applicant’s institution to permit a minimum of three days of attendance at the Annual Meeting. If accepted, applicants will be expected to participate in any planned activities for the awardees. They are required to submit a brief report commenting on the scientific sessions they attended at the Annual Meeting and the minority travel program.

Further information and application forms are available from the AACR office. Letters of reference should accompany the application. The deadline for receipt of applications will be January 26, 1996. Grants from this program are also available for attendance at AACR Special Conferences taking place in North America. The brochure for each meeting contains all necessary information.

AACR Special Conferences in Cancer Research
A number of meetings are now being organized in the AACR’s new series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for some of these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. FAX: (215) 440-9313. E-Mail: aacr@aol.com.

November 17–21, 1995
Novel Strategies against Resistant Cancers
Chairpersons:
VICTOR LING, Vancouver, B.C., Canada
DANIEL D. von Hoff, San Antonio, TX
Sanibel Harbour Resort & Spa, Ft. Myers, FL

February 19–25, 1996
Cancer Susceptibility Genes and Molecular Carcinogenesis
Chairpersons:
ALLAN BALMAIN, Glasgow, Scotland
CURTIS C. HARRIS, Bethesda, MD
KENNETH OLDEN, Research Triangle Park, NC
Keystone Resort, Keystone, CO

March 1–5, 1996
Proteases and Protease Inhibitors
Chairpersons:
LYNN M. MATRISIAN, Nashville, TN
BONNIE F. SLOANE, Detroit, MI
Marriott’s Bay Point Resort, Panama City Beach, FL

June 8–12, 1996
Inducible Genomic Responses
Chairpersons:
WILLIAM T. BECK, Memphis, TN
JOHN A. HICKMAN, Birmingham, England
RICHARD I. MORIMOTO, Evanston, IL
Skamania Lodge, Stevenson (Columbia River Gorge), WA
## AMERICAN SOCIETY OF CLINICAL ONCOLOGY

**Announces**

**YOUNG INVESTIGATOR AWARDS**

$32,500 for one-year period

Available to physicians in final year or who have recently completed their fellowship in oncology

**CAREER DEVELOPMENT AWARDS**

$52,000/year for three-year period

Available to physicians in first or second year as full-time, primary faculty appointment in a clinical department of an academic medical institute

**Application Deadline:** November 15, 1995

For Information and Application Forms:
American Society of Clinical Oncology
453 Michigan Avenue, Suite 1717, Chicago, IL 60611-4067
(312) 644-0828 • (312) 644-8557 FAX

---

### Statement of Ownership, Management, and Circulation

<table>
<thead>
<tr>
<th>Publication Title</th>
<th>Publication No.</th>
<th>Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Cancer Research</td>
<td>7</td>
<td>10/11/95</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>News Frequency</th>
<th>No. of Issues Published Annually</th>
<th>Annual Subscription Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly</td>
<td>10</td>
<td>$45.00</td>
</tr>
</tbody>
</table>

**Circulation Data**

- **Total Net Paid Circulation:** 5,100
- **Retail Net Paid Circulation:** 5,100
- **Total Paid Circulation:** 5,100
- **Retail Paid Circulation:** 5,100

**Statement of Ownership signed by Margaret Post, Ph.D., Executive Director**

10/11/95

---

**A CARROT HELPS MORE THAN JUST YOUR EYESIGHT.**

A carrot is rich in vitamins A and C, has zero fat, is a good source of fiber, and can help you fight cancer. For more information on fruits and vegetables that can do the same, call 1-800-ACS-2345.

---

**AMERICAN CANCER SOCIETY**

**THERE'S NOTHING MIGHTIER THAN THE SWORD.**
Instructions for Authors

Scope

Clinical Cancer Research, a new journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, and Associate Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the American Medical Association, P.O. Box 7046, Dover, DE 19903-7046. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Manuscript Submission

Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, at Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

The letter of submission should suggest the Associate Editor (or Editor-in-Chief) who will serve as primary reviewer of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of up to five potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:

Figures
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs will be charged to the authors. Submit color figures on flexible backing.

Typesetting Manuscripts from Computer Disks
Clinical Cancer Research welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, Telephone 212-639-6317, Fax 212-717-3629 or:
FIRST ANNOUNCEMENT

Call for Abstracts

87th Annual Meeting of the American Association for Cancer Research

April 20-24, 1996
Washington, DC

An Exciting Multidisciplinary Program for Laboratory and Clinical Cancer Researchers

In This Booklet:
- Abstract Submission Forms and Instructions
- Preliminary Program Information
- Information on Travel Awards for Young Basic and Clinical Investigators
- Advance Registration and Housing Forms
- AACR Membership Application Forms
- Employment Register Forms
1996 Annual Meeting
Titles of Major Sessions
(Confirmed Chairpersons in Parentheses)

American Association for Cancer Research

Special Plenary Session
Twenty-Fifth Anniversary of the National Cancer Act: Progress and Promise (Joseph R. Bertino)

Symposia
Apoptosis: Manipulating Programmed Cell Death in Cancer (David E. Fisher)
Matrix Metalloproteases and Inhibitors (Lynn M. Matrisian)
Cell Cycle: Targets for Therapy (Stephen H. Friend)
Endogenous DNA Damage: Detection and Biological Significance (John M. Essigmann)
Cell Signalling
Recent Developments in Gene Therapy (Drew M. Pardoll)
Tumor Chemoprevention in Humans (Thomas W. Kensler)
Genetic Predisposition to Cancer (Mark H. Skolnick)
Cell Responses to DNA Damaging Agents (Nathan A. Berger)
Drug Resistance: Transcriptional and Translational Mechanisms (Kathleen W. Scottu)
Monoclonal Antibodies: Clinical Mechanisms and Effectiveness (Lorraine J. Gudas)
Targeting Growth Factor Receptors for Therapy (John Mendelsohn)
Melanoma as a Clinical Model (Alan N. Houghton)
Thymidylate Synthetase and Its Inhibitors (Nathan A. Berger)
Nutrition and Cancer (Walter C. Willett)
Aberrant Transcription Factors and Malignancy (Lorraine J. Gudas)
Steroid Hormones: Breast and Prostate Cancer (Myles A. Brown)
Viral Mechanisms of Carcinogenesis (Harald zur Hausen)
Tumor Suppressor Genes (Bert Vogelstein)
Ovarian Cancer: From the Laboratory to the Clinic (Robert F. Ozols)
Drug Metabolizing Enzymes in Cancer Prevention and Therapy (Cecil B. Pickett)
Cell Adhesion Molecules and the Cytoskeleton (Hai Lin Guan and Rudolph L. Juliano)
Tumor Angiogenesis (Judah Folkman and Mark A. Goldberg)
Neuroblastoma: Recent Advances in Diagnosis and Treatment (Garrett M. Brodeur)
Telomerases, Cell Senescence, and Cancer (Calvin B. Harley)

Pre-Meeting Methods Workshops
Quantitative Biology and Pharmacodynamics (Robert C. Jackson)
Animal Models: Transgenic and Knockout Mice in Cancer Investigations

Controversy Sessions
Does Regional Chemotherapy Work? (David S. Alberts)
Is Beta-Carotene Useful in Cancer Prevention? (Waan Ki Hong)
In Studies of Drug Resistance, Have Preclinical Models Provided Accurate Predictions for Clinicians? (Bruce A. Chabner)
Is p53/Rb Important for Therapeutic Outcome? (William F. Benedict)
Should Genetic Testing Be Done on Patients to Assess Cancer Risk? (Judy E. Garber)

Meet-The-Expert Sunrise Sessions
Quantitative PCR As a Tool to Detect Minimal Residual Disease in Lymphoma and Leukemia (John Gibben)
Inhibition of Tobacco-induced Carcinogenesis (Stephen S. Hecht)
Cell Cycle (Peggy J. Farnham)
Drugs Which Interact with Microtubules: An Update (Eric K. Rowinsky)
Culturing Normal and Neoplastically Transformed Human Epithelial Cells (Martha R. Stampfer)
Mammary Carcinogenesis (Daniel Medina)
Radiation Sensitization (Theodore S. Lawrence)
NMR As a Prognosticant (Jerry D. Glickson)
Antiestrogens (V. Craig Jordan)
DNA Topoisomerases and Their Inhibitors (Yves G. Pommier)
Estrogens and Breast Cancer (Lovell A. Jones)
Tumor Physiology (Rakesh K. Jain)
Protein Kinase C in Cell Transformation (Samantha Jaken)
Environmental Carcinogens: Their Impact in Cancer (John A. McLachlan)
Lung Cancer: A Primer (Garrett M. Brodeur)
Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques (Funmi I. Olopade)
Tumor Vaccines (Jeffrey Schlom)
Challenges in Bone Marrow Transplantation (William S. Dalton)
Immunologic Features of AIDS Pathogenesis (Jay A. Levy)
Natural Killer Cells (Ronald B. Herberman)
Interferons and Cancer (Ernest C. Borden)
Transcription Factors As Therapeutic Targets (Richard A. Heyman)
Chemokines and Leukocyte-specific Chemotactic and Activating Factors (Barrett J. Rollins)
Bcl and Cell Death (Stanley J. Korsmeyer)
Prodrugs (Peter D. Senter)
Reconstruction of Complex Tissues in Culture (Diane F. Birt)
Childhood Leukemias: The Latest in Treatment (Steven E. Sallan)

April 20-24, 1996
Washington, D.C.
Convention Center

The Latest Developments in All Areas of Cancer Research
Program Chairperson: Lorraine J. Gudas

Major Presentations by the Foremost Scientists in the Field
Minisymposia, Poster Discussion Sessions, and Poster Sessions of Proffered Papers

Abstract Deadline: December 1, 1995

For More Information:
AACR Office
Public Ledger Building
Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300
Fax 215-440-9313
Email aacr@aol.com

An Essential Multidisciplinary Program for Laboratory and Clinical Cancer Researchers
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TENTATIVE SCHEDULE OF EVENTS</td>
<td>2s</td>
</tr>
<tr>
<td>MEETING OVERVIEW</td>
<td>3s</td>
</tr>
<tr>
<td>ACKNOWLEDGMENT CARD</td>
<td>Following Page 4s</td>
</tr>
<tr>
<td>REGULATIONS APPLYING TO ABSTRACTS AND PROFFERED PAPERS</td>
<td>5s</td>
</tr>
<tr>
<td>INSTRUCTIONS FOR PREPARATION AND MAILING OF ABSTRACTS</td>
<td>6s</td>
</tr>
<tr>
<td>ABSTRACT CATEGORY/SUBCLASSIFICATION LIST</td>
<td>10s</td>
</tr>
<tr>
<td>SAMPLE ABSTRACT FORM</td>
<td>12s</td>
</tr>
<tr>
<td>OFFICIAL ABSTRACT FORM FORMS</td>
<td>13s</td>
</tr>
<tr>
<td>ACTIVE AND CORRESPONDING MEMBER FORMS</td>
<td>17s</td>
</tr>
<tr>
<td>ASSOCIATE MEMBERSHIP APPLICATION FORMS</td>
<td>19s</td>
</tr>
<tr>
<td>EMPLOYMENT REGISTER FORMS</td>
<td>21s</td>
</tr>
<tr>
<td>HOTEL RESERVATION INFORMATION</td>
<td>25s</td>
</tr>
<tr>
<td>TRAVEL AWARDS</td>
<td>28s</td>
</tr>
<tr>
<td>AUDIOTAPE ORDER FORM (1995 Annual Meeting)</td>
<td>29s</td>
</tr>
<tr>
<td>ADVANCE REGISTRATION FORM</td>
<td>31s</td>
</tr>
<tr>
<td>FORTHCOMING AACR SCIENTIFIC MEETINGS</td>
<td>32s</td>
</tr>
<tr>
<td>BOARD OF DIRECTORS AND ANNUAL MEETING COMMITTEES</td>
<td>33s</td>
</tr>
</tbody>
</table>
1996 AACR ANNUAL MEETING

TENTATIVE SCHEDULE OF EVENTS

Saturday, April 20

11:00 a.m.-8:00 p.m.  On-site Registration
12:00 noon-6:30 p.m.  Educational Sessions
2:00-6:00 p.m.          Methods Workshops (advance registration required; forms available in November)
6:30-8:00 p.m.          WICR Guest Lecture and Reception
8:00-10:00 p.m.         Opening Mixer

Monday, April 22 (cont.)

1:00-2:00 p.m.           American Cancer Society Lecture
1:00-2:00 p.m.           Controversy Sessions
1:00-5:00 p.m.           Poster and Poster Discussion Sessions
1:45-5:15 p.m.           Minisymposia
2:15-5:15 p.m.           Symposia
5:30-6:00 p.m.           Presentation by the Director of the NCI
6:00-7:00 p.m.           Annual Business Meeting

Sunday, April 21

7:00 a.m.-4:00 p.m.      On-site Registration
7:00-8:00 a.m.           Meet-the-Expert Sunrise Sessions
8:00 a.m.-12:00 noon     Poster and Poster Discussion Sessions
8:15-11:45 a.m.          Minisymposia
8:30-11:30 a.m.          Plenary Session: "25th Anniversary of the National Cancer Act: Progress and Promise," Joseph R. Bertino, Chairperson
11:45 a.m.-12:45 p.m.    Clowes Memorial Award Lecture (sponsored by Eli Lilly & Company)
12:30-5:00 p.m.          Exhibit Show Open
1:00-2:00 p.m.           Controversy Sessions
1:00-5:00 p.m.           Poster and Poster Discussion Sessions
1:45-5:15 p.m.           Minisymposia
2:15-5:15 p.m.           Symposia
5:30-6:30 p.m.           Presidential Address: Joseph R. Bertino
6:30-9:00 p.m.           Minority Issues Committee Symposium
8:00-10:30 p.m.          Annual Reception

Monday, April 23

7:00 a.m.-4:00 p.m.      On-site Registration
7:00-8:00 a.m.           Meet-the-Expert Sunrise Sessions
8:00 a.m.-12:00 noon     Poster and Poster Discussion Sessions
8:00-11:00 a.m.          Symposia
8:15 a.m.-11:45 a.m.     Minisymposia
11:00 a.m.-5:00 p.m.     Exhibit Show Open
11:45 a.m.-12:45 p.m.    Rosenthal Foundation Award Lecture
1:00-2:00 p.m.           Late-Breaking Research Session
1:00-5:00 p.m.           Poster and Poster Discussion Sessions
1:45-5:15 p.m.           Minisymposia
2:15-5:15 p.m.           Symposia
5:30-6:30 p.m.           Rhoads Memorial Award Lecture (sponsored by an anonymous donor)

Wednesday, April 24

7:00 a.m.-2:00 p.m.      On-site Registration
7:00-8:00 a.m.           Meet-the-Expert Sunrise Sessions
8:00 a.m.-12:00 noon     Poster and Poster Discussion Sessions
8:00-11:00 a.m.          Symposia
8:15 a.m.-11:45 a.m.     Minisymposia
11:45 a.m.-12:45 p.m.    Cain Memorial Award Lecture (sponsored by Warner-Lambert)
1:00-2:00 p.m.           Controversy Session
1:00-5:00 p.m.           Poster and Poster Discussion Sessions
1:45-5:15 p.m.           Minisymposia
2:15-5:15 p.m.           Symposia
OUTSTANDING SCIENTIFIC PROGRAM

- The latest findings in the most rapidly developing areas of basic, clinical, and translational cancer research.

- International scientific scope.

- Invited presentations on the most promising advances in the field in a variety of formats.

- Program Committee of scientific leaders headed by Lorraine J. Gudas, Chairperson of the Department of Pharmacology, Cornell University Medical School.

- Outstanding Plenary Session (“25th Anniversary of the National Cancer Act: Progress and Promise”) chaired by President Joseph R. Bertino, Chairperson of the Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center. Distinguished speakers: Harold Varmus, Arnold J. Levine, Susan Band Horwitz, Lloyd J. Old, Paul Talalay, and James F. Holland.

- Two new special lectures on clinical cancer research and cancer prevention.

- Nearly 4,000 proffered papers covering all aspects of cancer research.

- Late-breaking Research Session for the presentation of important findings made after the abstract deadline (December 1, 1995).

- Opportunities to interact with prominent scientists in “Meet-the-Expert” Sunrise Sessions.

- Conflicting views of a major scientific issue in controversy sessions.

- Comprehensive overviews of important disciplines in Educational Sessions.

- Reviews of state-of-the-art research techniques in Methods Workshops.

A FORMAT THAT PROMOTES SCIENTIFIC INTERACTION AND REDUCES TRAVEL COSTS

- Meeting date in mid-April, well before the June 1 NIH grant submission deadline and the Memorial Day Holiday.

- Educational Sessions and Methods Workshops on Saturday afternoon and a full complement of sessions on Sunday morning allowing registrants to obtain reduced airfares that require a Saturday night stayover.

- Four full days of scientific sessions to reduce overlaps in topics.

- A schedule that allows time for visiting posters and exhibits with no major sessions conflicting.

MEETING PUBLICATIONS THAT BECOME VALUABLE REFERENCE TOOLS

- Proceedings of the American Association for Cancer Research with abstracts of 4,000 proffered papers and over 100 invited presentations.

- Annual Meeting Program with the complete meeting schedule and titles and authors of all presentations.

- NEW THIS YEAR: Annual Meeting Abstracts on CD-ROM, with powerful search capabilities.

OTHER SERVICES AND PROGRAMS IMPORTANT TO PROFESSIONAL DEVELOPMENT

- Exhibit Show with products and services essential to laboratory and clinical research programs.

- Listings of available positions and candidates in the AACR Employment Register.

- Varied educational and mentorship program from Women in Cancer Research (WICR).
• Symposium on careers in cancer and biomedical research organized by the Minority Issues Committee.

• Opportunities to meet with NIH Program and Review Staff in NIH Resource Room.

AN ACCESSIBLE AND CONVENIENT MEETING SITE

• Washington, DC, easily reached from all major cities, particularly those on the U.S. East Coast.

• All scientific sessions in the Washington Convention Center.

• Convenient Co-Headquarters Hotels, the Washington Renaissance and the Grand Hyatt, both just across the street from the Center.

• A variety of other hotels within a 1-mile radius, connected to the Center by shuttle buses.

• Discounted airfares from the Association’s Official Travel Agent, Uniglobe, at (800) 243-4370 or (215) 628-3322. FAX: (215) 628-0310.

AN EXPANDED PROGRAM OF ANNUAL MEETING TRAVEL GRANTS

• Awards for medical and graduate students, physicians in training, and postdoctoral fellows who are authors of outstanding abstracts. (To qualify submit an abstract and check Box 7A on the abstract form for automatic consideration.)

• Awards from the Comprehensive Minority Biomedical Program of the NCI for medical and graduate students, physicians in training, and postdoctoral fellows from minority groups considered underrepresented in cancer research, i.e., African Americans, Hispanic Americans, Native Americans, Native Pacific Islanders, and Alaskan Americans. (To apply check Box 7B on the abstract form or call the AACR Office for an application form. Application deadline: January 26, 1996.)

• Glaxo Wellcome Oncology Clinical Research Scholar Awards made to physicians in training and postdoctoral fellows nominated by selected cancer centers and institutes. (Centers wishing to be considered for 1996 Awards should call the AACR Office.)

• WICR’s Brigid Leventhal Travel Awards for graduate and medical students, physicians in training, and postdoctoral fellows who have submitted abstracts for the meeting and have been nominated by a member in good standing of WICR. (For more information contact Dr. Mary Jean Sawey at 215-898-0270.)

HOW TO PARTICIPATE IN THE 1996 ACR ANNUAL MEETING


2. Register for the meeting using the advance registration form on Page 31. Send the form with payment by March 1, 1996, to obtain reduced registration rates and to ensure the receipt of your badge and meeting publications in advance of the annual meeting.

3. Review the Proceedings on CD-ROM in advance of the meeting by adding $35 (members) or $45 (nonmembers) to your advance registration fee payment. Check the appropriate box on the registration form.

4. Reserve a hotel room. On Page 25 you will find instructions for using the AACR Housing Bureau in Washington. Please note that registrants from North America should register by telephone. A FAX number is provided for registrants from other countries. Page 26 contains a list of all hotels reserving rooms for the AACR meeting as well as sleeping room rates, and Page 27, a map showing the convention center, the meeting hotels, and other important landmarks in Washington, DC. Make your reservation as soon as possible to obtain your first-choice hotel room and, in any case by March 21, 1996.

5. Join the AACR. Application forms for active and corresponding membership appear on Pages 17-18, and for associate membership, on Pages 19-20. Application for membership has now been facilitated: Now

• Corresponding members may now sponsor candidates for corresponding, active, and associate membership.

• Eligible scientists from outside of North America may now apply for associate membership.

• The next deadline for applications for active and corresponding membership is January 1, 1996.

THE ACR MEETING IN WASHINGTON, APRIL 20-24, 1996,
AN ESSENTIAL SCIENTIFIC MEETING FOR ALL CANCER RESEARCHERS
AMERICAN ASSOCIATION FOR CANCER RESEARCH
87th ANNUAL MEETING
Washington Convention Center • Washington, D.C. • April 20-24, 1996

Deadline for Receipt of Abstracts at the AACR Office
DECEMBER 1, 1995

Regulations Applying to Abstracts and Proffered Papers

Authors who submit an abstract of a paper for consideration for presentation at the annual meeting of the American Association for Cancer Research (AACR) confirm that they have not previously published these data, that they have not previously presented them at a national scientific meeting, and that they are not planning to publish or present them prior to the dates of the AACR Annual Meeting. AACR policy states that the content of submitted abstracts is kept strictly confidential by the members of the Program Committee during review and the pre-publication processing. After review of the abstract by the Program Committee the author will be notified about its acceptability for presentation. The paper given at the annual meeting must coincide directly with the scientific content of the submitted abstract. If for any reason this is not possible, the paper must be withdrawn from presentation. Only those abstracts that are deemed acceptable for presentation by the Program Committee will be published in the Proceedings of the American Association for Cancer Research to be issued in March 1996. N.B. Authors will be charged for any production costs incurred as a result of the withdrawal of abstracts after the content of the Proceedings is in press.

To maximize the effectiveness of the scientific program the Program Committee has full discretion to assign papers to minisymposia, poster discussion sessions, and poster sessions.

Minisymposia. Minisymposia will be planned from submitted abstracts. This format serves as a vehicle for the presentation and extensive discussion of developments in timely areas of cancer research.

Authors whose papers are assigned to minisymposia will be informed about the amount of time available for the delivery of their papers. At appropriate intervals, there will be opportunities for the discussion of each paper presented during the session. In addition, these sessions will include an introduction and a concluding discussion of the topic.

The Program Committee has identified a number of topics as being suitable for minisymposia and strongly encourages the submission of abstracts in these areas. If a sufficient number of high-quality abstracts are submitted and accepted on these topics, minisymposia will be devised. Authors who submit abstracts in these areas should note that their papers may be scheduled in poster sessions if they cannot be accommodated in minisymposia. Authors need not designate their interest in these sessions on the abstract form; the Program Committee will use computer-aided search techniques to identify appropriate submissions.

Potential Minisymposium Topics
Targeting of Drugs to DNA Replication and Repair
Novel Natural Products as Chemotherapeutic Agents
Lipid Second Messengers
Cancers of the Central Nervous System: Characterization and Treatment
Leukemias and Lymphomas of Childhood: Molecular Analysis and Treatment
Radiation Therapy: Recent Advances
Molecular Analysis of Metastasis
Tumor Necrosis Factor
Cis-Platinum: Mechanism of Action and Therapeutic Approaches
Biology of Neural Crest-derived Tumors

Poster Discussion Sessions. Poster discussion sessions will also be scheduled from submitted abstracts and will run for four hours. The presentation of posters is supplemented by a focussed discussion of the research areas under consideration. After presentation of the posters, there will be a one-hour discussion period led by two chairpersons. Participants will have an opportunity to view the posters again after the discussion.

Prior to the annual meeting, the two chairpersons of these sessions will communicate directly with the authors presenting in the session to obtain more information on the work to be discussed. Authors will be expected to submit the content of their posters to the two chairpersons well in advance of the meeting to maximize the effectiveness of the discussion at the annual meeting.

Poster Sessions. Regular poster sessions will extend for four hours. Authors will be required to be present at their posters for the first three hours of the session. Detailed instructions for the preparation of posters will be sent to all authors whose abstracts are accepted for these sessions.

The Association will do its utmost to assist any author who, for religious reasons, cannot present a paper on a particular day of the week. However, the complexities of scheduling thousands of papers for this multidisciplinary cancer research meeting require that sufficient notice from authors be given to the Program Committee. Authors who need special assistance with regard to the scheduling of their papers must enclose written requests along with their submitted abstracts.

SPONSORSHIP REGULATIONS

1. The SPONSOR must be a member of the Association in good standing. That is, an active, corresponding, or associate member must have paid his or
her membership dues through 1995 by the time of the submission of the abstract in order to serve as the SPONSOR of one abstract for the upcoming annual meeting. As stated in the AACR By-Laws, honorary and emeritus members are exempt from the payment of dues; thus this regulation does not apply to them.

An associate member in good standing may SPONSOR his or her own abstract provided that (a) he or she is the PRESENTER of the abstract, and (b) an active or corresponding member in good standing also signs the abstract form ENDORSING the work. The ENDORSER does not thereby lose his or her own sponsorship privilege.

Note: An associate member may SPONSOR only one (namely, his or her own) abstract.

2. Each member of the Association may SPONSOR only one abstract. This privilege may be used in one of two ways: (a) the SPONSOR may be one of the authors of the abstract, or (b) the SPONSOR may sign the abstract form on behalf of the authors who may be either members or nonmembers of the Association. (As noted above, an associate member may SPONSOR only an abstract that he or she PRESENTS.)

3. The SPONSOR must sign the abstract form in the space provided.

4. A member or nonmember may be listed as a coauthor on more than one abstract, provided that each abstract has a different member SPONSOR.

5. The SPONSOR is obligated to ascertain that all authors are aware of the content of the abstract. Sponsorship of an abstract implies support for the data and interpretations contained therein.

Please do not submit applications for active/corresponding membership along with your abstracts. The closing date for receipt of these applications was September 1.

| COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE SPONSOR. |
| Adherence to these rules will be verified. Violations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. |

| ABSTRACT SUBMISSION FEE |
| A fee of US$35 will be assessed for each abstract submitted for consideration by the Program Committee. This fee offsets some of the costs of processing the abstract. Each abstract must be accompanied by a check or purchase order for US$35 payable to the American Association for Cancer Research, Inc. - OR - authorization must be provided to charge this fee to a credit card that is accepted by the AACR (see Item 9 on the abstract form). All checks must be drawn on United States banks. If a purchase order must precede payment by an institution, it is the PRESENTER's responsibility to ensure that the purchase order is followed by payment of the fee. Please list the name of the PRESENTER on the check or purchase order. |
| In cases of the voluntary withdrawal of an abstract by the author, the return of the abstract because of violation of abstract regulations, or the rejection of the abstract for presentation, the submission fee will not be refunded. |

Instructions for the Preparation and Mailing of Abstracts

| ABSTRACT FORM |
| Abstracts must be submitted on the official blue and white abstract form provided by the Association. FAX TRANSMITTALS WILL NOT BE ACCEPTED. |
| Enclosed are TWO abstract forms. Please pass one on to a colleague if you do not need it for your own use. Additional abstract forms may be obtained by calling or by writing to the AACR Office. |
| A Temporary Abstract Number will be assigned to your abstract when it arrives at the AACR Office. Its number will be listed on the card that is returned to you acknowledging receipt of your abstract. Please reference the Temporary Abstract Number in all subsequent communications with the AACR Office. |
| The official abstract form must be completely filled out and signed in accordance with the instructions. Two (2) photocopies of the completed form must also be submitted. In addition to typing the abstract within the blue border according to the instructions given below, please provide the information and signatures requested on the abstract form as follows. (N.B. The numbered headings below correspond to the numbers on the abstract form.) |

1. Category and Subclassification. Choose ONLY ONE category and subclassification. Indicate the category and subclassification in which your paper belongs by typing the appropriate five-character code in the blocks provided. A list of codes for the categories and subclassifications appears on Pages 10-11 of this booklet. These designations will serve as a guide to the Program Committee in the grouping of abstracts but will not necessarily be the actual titles of scientific sessions to be held at the annual meeting.

2. Sponsor of the Abstract. Type the member number, name, address, telephone number, and FAX number of the member using his or her membership privilege to SPONSOR the abstract. (Member numbers can be found on an individual's membership card and in the AACR Directory of Members.) The SPONSOR, who must be a member of the AACR in good standing through 1995, may SPONSOR only one abstract. (See Page 4 for Sponsorship Regulations.)

3. Sponsor Signature. The SPONSOR must sign the form in the space provided to indicate support for the data and interpretations contained in the abstract and to transfer the copyright of the abstract to the American Association

4. Associate Members Only. If an associate member is the SPONSOR AND PRESENTER of the abstract, he or she must ask an active or corresponding member in good standing or an emeritus or honorary member to sign Line 4 of the form as an ENDORSEMENT of the work. Type the name and member number of the ENDORSING member on the appropriate lines.

5. Identification of Financial Interests (if any). Check this box if any author of the abstract has a financial interest in products or processes involved in the research described. Financial interest includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships. If the box is checked, describe the financial interest(s) on a separate sheet.

6. Presenter of Abstract. Type the name, AACR member number (if applicable), address, telephone number, and FAX number of the PRESENTER of the paper in the space provided. It is generally expected that the first author of an abstract will be its PRESENTER.

7. Eligibility for Travel Awards.
   A. Indicate whether the PRESENTER of the abstract is a medical student, graduate student, physician in training, or postdoctoral fellow. PRESENTERS who meet these requirements and who are first authors on abstracts rated highly by the Program Committee may be candidates for a travel award. If a PRESENTER is eligible based on the above criteria and is under consideration, a letter confirming his or her status on the official letterhead of the PRESENTER's institution and signed by the registrar, dean, or department head of that institution will be requested at a later date.

   B. If the PRESENTER meets the criteria in the paragraph above, check this box if the PRESENTER is also Black, Hispanic, American Indian, Native Alaskan, or Native Pacific Islander. The Comprehensive Minority Biomedical Program of the National Cancer Institute funds a program of travel grants administered by the AACR to encourage participation in the annual meeting by minority groups which have traditionally been underrepresented in cancer research.

Eligible scientists are young, full-time predoctoral students, postdoctoral fellows, and physicians in training who are either engaged in cancer research, or who have training that could lead to contributions in this field. By action of the AACR Board of Directors, only citizens of the U.S. and Canada or scientists who are permanent residents in those countries may receive one of these NCI awards to minority scientists. Awardees will be selected on the basis of qualifications, references, and an estimation of potential benefit by an advisory committee consisting of members of AACR who will review a completed application and letters of reference. The award will consist of partial support of registration, travel, and subsistence expenses incurred in connection with attendance at the annual meeting.

Persons checking this box will receive an application form which must be completed and returned to the AACR by January 26, 1996. Applicants will be chosen both from minority institutions and the larger bodies of universities and research institutions. Awardees are expected to attend at least three full days of scientific sessions. Along with their requests for reimbursement of relevant expenses, they must submit a brief report commenting on the scientific sessions they attended at the meeting.

8. Presenter Signature. The PRESENTER of the paper must sign the form in the space provided to give the Association permission to arrange for audiotape recording and the subsequent sale of audiotape cassettes of the papers delivered orally at the 1996 Annual Meeting. Your advance permission for this taping in the event that your paper is among those to be recorded is appreciated.

NOTE: If the PRESENTER is also the SPONSOR of the abstract, he or she must sign the form on Line 3 as well as Line 8.

9. Authorization to Charge Credit Card for US$35 Abstract Submission Fee. If you want the Abstract Submission Fee (US$35) to be billed to your credit card, please fill in the necessary information and sign in the space provided.

ABSTRACTS SUBMITTED IN VIOLATION OF ANY OF THE ABOVE REGULATIONS, I.E., ABSTRACTS WITHOUT A CATEGORY AND SUBCLASSIFICATION (LINE 1), WITHOUT THE NAMES OF THE SPONSOR AND PRESENTER (LINES 2 AND 6), OR WITHOUT THE REQUIRED SIGNATURES (LINES 3 AND 8) WILL BE SUBJECT TO AN ADMINISTRATIVE CHARGE OF US$35.

CONTENT OF ABSTRACTS

As stated previously, authors who submit an abstract of a paper confirm that they have not previously published these data, that they have not previously presented them at a national scientific meeting, and that they are not planning to publish or present them prior to the dates of the AACR annual meeting.

Members of the Program Committee will evaluate the scientific quality of the submitted abstract on the basis of the following criteria: novelty of the research, significance of the findings, and clarity of the presentation. Authors should be particularly cognizant of the importance of setting forth the objectives and hypotheses of the study in a clear and succinct manner and of summarizing the new, unpublished results. If the abstract is poorly written such that the Program Committee cannot determine its novelty and importance, the acceptance of the paper for presentation at the annual meeting will be jeopardized.

1. Abstracts must describe in a succinct manner the purposes and results of the research so that the quality, originality, and comprehensiveness of the work can be evaluated by the Program Committee. Each abstract should contain: (a) an introductory sentence indicating the purpose of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.
Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature.

2. Titles should be indicative of the content of the abstract. All words necessary to identify the subject matter should be included in the title to facilitate information retrieval and online searches. Periods (not dashes or other punctuation) should be used to separate two-part titles. Abbreviations are not permitted in titles.

3. Abbreviations may be used in the body of an abstract if they are defined at their first mention in the text. Complex therapeutic regimens must be identified. The chemical structure, method of preparation, and patent or reference numbers of chemical compounds should be provided in the abstract.

4. Illustrations and tables are unacceptable within abstracts.

5. Supplementary data submitted along with the abstract will not be transmitted to the Program Committee for review.

**FORMAT OF ABSTRACTS**

Errors made on the original abstract form will appear in the published abstract. Therefore, careful preparation and proofreading are essential. Only abstracts submitted on the official abstract form will be considered by the Program Committee. There is a limited supply of these forms. Therefore, before the abstract is typed on the final form, all instructions and the sample abstract should be read thoroughly.

Abstracts must be prepared in accordance with the approved format demonstrated in the sample abstract (Page 12). Please note in particular the following regulations concerning format:

1. The entire abstract, including text, title, authors, and affiliations, must fit within the blue lines provided.

2. The abstract must not be mechanically reduced to fit into the box provided.

3. The first line of the title should be flush with the left margin of the abstract box.

4. The heading must include: the title of the paper with ONLY THE FIRST LETTER OF THE FIRST WORD CAPITALIZED and the rest in lower case (except where lower case is incorrect, e.g., the word "DNA"), the authors' names (as a group, with surnames first and given names last), their institutional affiliations, cities, states in abbreviated forms, zip codes, and countries. If possible, please print the title in **boldface** letters.

Abbreviations are not permitted in titles. Abbreviations may be used in the body of the abstract if they follow in parentheses immediately after the term being abbreviated at the first usage of that term in the text.

5. Academic degrees should be omitted to save valuable space.

6. The abstract should be printed single spaced in one paragraph. Abstracts should not be printed using dot-matrix printers. Abstracts may be prepared using typewriters or daisy-wheel printers with a sharp black ribbon and a printing element no smaller than 12-pitch (elite). Abstracts may also be printed using laser or ink-jet printers with type no smaller than 10-point.

7. Any symbols that must be drawn by hand should be drawn with black ink.

**ABSTRACTS OR ABSTRACT HEADINGS THAT DO NOT CONFORM TO THE REQUIRED FORMAT WILL BE RETYPED AT A COST OF US$35 TO THE SPONSOR.**

**PLEASE DIRECT QUESTIONS REGARDING THE PREPARATION OF ABSTRACTS TO 215/440-9300.**

**SUBMISSION OF CORRECTED ABSTRACTS**

If after mailing your abstract you discover an error, please do not submit a corrected abstract until you have received an acknowledgment card containing the Temporary Abstract Number of your original submission. You may then submit a corrected abstract in strict accordance with the following instructions:

1. On a photocopy of the original abstract, indicate the correction(s) you are making.

2. On an official abstract form, print the full text of the revised abstract in the space provided and answer all questions on the form.

3. On both forms write your Temporary Abstract Number and the word "Resubmission" in the box in the upper right hand corner labeled Temp. Abst. No.

4. Send the corrected original abstract and the revised abstract on the official form to the address given on the next page. In addition, write or type the word "Resubmission" on the mailing envelope.

Authors may be charged for any production costs incurred as a result of abstracts being resubmitted after the Proceedings issue goes to press. The Association will not be responsible for the acceptance and processing of revised abstracts not submitted in compliance with the above regulations. No substantive changes may be made in abstracts after they have undergone scientific review, and the Association cannot accept any resubmission that will delay the publication of the Proceedings.

**MAILING INSTRUCTIONS**

1. Abstracts must be received in the office of the American Association for Cancer Research no later than December 1, 1995. Submission at an earlier date would be appreciated. The Association urges investigators working outside of the United States to send their abstracts well ahead of the deadline date or to use one of the international courier services that offer delivery within a few days. The
deadline for receipt must be applied uniformly to all abstracts regardless of their origin. **FAX or other electronic transmittals will not be accepted.**

2. The following material should accompany the official abstract form:

   A. Two (2) legible copies of the completed form.

   B. A check or purchase order for US$35 payable to the American Association for Cancer Research, Inc. All checks must be drawn on United States banks. **PLEASE LIST THE NAME OF THE PRESENTER ON YOUR CHECK OR PURCHASE ORDER.** If you wish us to charge this amount to your credit card, fill out and sign Item 9 on the abstract form.

   C. The Acknowledgment Card attached to this announcement. The names of the authors and the title of the paper should be filled in on the card prior to submission. The card will be returned to you showing the Temporary Abstract Number assigned to your abstract. This number should be referenced in all correspondence or telephone calls to the AACR Office. **PRESENTER:** To ensure receipt of the Acknowledgment Card, put your own address on the reverse of the card and affix proper postage.

   D. One stamped, regular letter-sized envelope (about 4 x 9 1/2 inches, 10.2 x 24.2 cm.) addressed to the PRESENTER. The final decision of the Program Committee concerning acceptability for presentation and publication will be returned in this envelope along with any other necessary instructions.

3. A check, purchase order, or credit card number in payment of US$35.; the original abstract form with the signatures of the SPONSOR and PRESENTER; 2 copies of the completed form; the completed, self-addressed, stamped Acknowledgment Card; and one self-addressed, stamped envelope should all be mailed unfolded and with cardboard backing in an envelope of suitable size to:

   American Association for Cancer Research, Inc.
   ATTENTION: 1996 ANNUAL MEETING ABSTRACT
   Public Ledger Building, Suite 816
   150 S. Independence Mall West
   Philadelphia, PA 19106-3483

4. Please do not enclose membership application forms, membership dues, advance registration forms, housing forms, or any other materials in the envelope with your abstract form and the related material requested in Item 3 above.

   N.B. Special mailing charges cannot be paid by the AACR. The AACR staff cannot assume responsibility for abstracts that are not delivered directly to the premises.

---

**THE DECEMBER 1, 1995, DEADLINE WILL BE STRICTLY ENFORCED.**
1996 ABSTRACT CATEGORIES AND SUBCLASSIFICATIONS

Type the five-character code for the appropriate category and subclassification in the blocks provided on Line 1 of the Abstract Form. There is some overlap among subclassification topics across the major abstract categories. To classify your abstract, first choose the category (printed in boldface) that best describes the primary emphasis of your work. Then select an appropriate subclassification within that category. Please note that many of the traditional abstract categories have been divided into sections to facilitate the distribution of abstracts to appropriate reviewers.

The highly specific subclassifications will serve as a guide to the Program Committee in the selection and grouping of abstracts for particular sessions but will not necessarily be the actual titles of scientific sessions to be held at the annual meeting. Decisions regarding titles of sessions will be made at the discretion of the Program Committee.

BIOLOGY
Cell Cycle
BL1-01 Cell cycle checkpoints
BL1-02 Cell cycle genetic alterations
BL1-03 Other

Cell Growth and Death
BL2-01 Apoptosis
BL2-02 Biological aspects of drug resistance
BL2-03 Biomarkers
BL2-04 Cell and tissue kinetics/flow microfluorometry
BL2-05 Host-tumor relationships
BL2-06 Tumor heterogeneity

Cell Signaling
BL3-01 Cell surface receptors
BL3-02 Extracellular matrix
BL3-03 Growth factors and differentiation
BL3-04 Integrins
BL3-05 Shape and cytoskeleton
BL3-06 Signal transduction

Invasion and Metastasis
BL4-01 Angiogenesis/pathophysiology
BL4-02 Cell adhesion molecules
BL4-03 Cell motility and migration
BL4-04 Human tumor xenografts
BL4-05 Invasion and metastasis
BL4-06 Mechanisms of bone metastasis
BL4-07 Proteases and their inhibitors

CARCINOGENESIS
Biomarkers, Premalignant Lesions, Risk Assessment
CG1-01 Biomarkers of exposure to carcinogens
CG1-02 Fish carcinogenesis
CG1-03 Genetic susceptibility
CG1-04 Predictive assays for carcinogenicity
CG1-05 Premalignant lesions
CG1-06 Risk assessment and toxicology
CG1-07 Other

Carcinogen Metabolism, DNA Damage and Repair, Genetic Alterations, Mutagenesis
CG2-01 DNA adducts: identification and conformational effects
CG2-02 DNA adducts: repair and sequence specificity
CG2-03 Genetic and cytogenetic alterations in human tumor cells
CG2-04 Metabolism and activation of carcinogens in animal models
CG2-05 Metabolism and activation of carcinogens in humans
CG2-06 Molecular responses to DNA damage

Carcinogen Metabolism, DNA Damage and Repair, Genetic Alterations, Mutagenesis (cont.)
CG2-07 Mutagenesis
CG2-08 Mutational spectrum of carcinogens
CG2-09 Oxygen radicals

Promotion and Progression/Communication
CG3-01 Cellular transformation
CG3-02 Growth factors
CG3-03 Mesenchymal/epithelial interactions
CG3-04 Radiation carcinogenesis and cell signalling
CG3-05 Signal transduction
CG3-06 Tumor progression
CG3-07 Tumor promotion

CLINICAL INVESTIGATIONS
Phase I Trials
CI1-01 Phase I studies

Phase II and III Trials
CI2-01 AIDS-related malignancies
CI2-02 Brain/central nervous system cancers
CI2-03 Breast cancer
CI2-04 Colon/gastrointestinal cancer
CI2-05 Genitourinary tract cancers
CI2-06 Gynecological cancers
CI2-07 Head and neck cancer
CI2-08 Hematological malignancies
CI2-09 Lung cancer
CI2-10 Melanoma
CI2-11 Pediatric malignancies
CI2-12 Prostate cancer
CI2-13 Other

Clinical Pharmacology
CI3-01 Drug resistance
CI3-02 Hematopoietic colony-stimulating factors
CI3-03 Mechanisms of drug action in humans
CI3-04 Pharmacokinetics and pharmacodynamics
CI3-05 Primary and adjuvant chemotherapy; multimodality therapy

Other Clinical Investigations
CI4-01 Autologous and allogeneic bone marrow transplantation
CI4-02 Chemoprevention/intermediate endpoints
CI4-03 Clinical endocrinology
CI4-04 Clinical trials methodology
CI4-05 Cytogenetics and clinical molecular genetics

Other Clinical Investigations (cont.)
CI4-06 Cytokines and growth factors
CI4-07 Diagnostic/prognostic response prediction
CI4-08 Differentiation therapy
CI4-09 Etiology and natural history of tumors
CI4-10 Gene therapy
CI4-11 Oncogenes in diagnosis and prognosis
CI4-12 Prevention of second cancers
CI4-13 Supportive care
CI4-14 Surgical oncology
CI4-15 Other

ENDOCRINOLOGY AND SIGNAL TRANSDUCTION
EN1-01 Cytokines and receptors
EN1-02 Growth factors and cell surface receptors
EN1-03 Hormonal carcinogenesis
EN1-04 Hormonal control of cell growth and cell death
EN1-05 Hormone action and inhibitors
EN1-06 Hormone synthesis, metabolism, and inhibitors
EN1-07 Hormones and differentiation
EN1-08 Neuroendocrine and other endocrine factors
EN1-09 Retinoids and receptors
EN1-10 Signal transduction
EN1-11 Steroid receptors/nuclear receptors
EN1-12 Thyroid hormones and receptors

Organ Sites
EN1-13 Breast
EN1-14 Ectopic hormone production
EN1-15 Gynecological
EN1-16 Prostate/Gynecological
EN1-17 Other
EN1-18 Other

EPIDEMIOLOGY AND PREVENTION
Epidemiology
EP1-01 Biomarkers in epidemiology
EP1-02 Cancer in minority populations
EP1-03 Descriptive epidemiology
EP1-04 Environmental and occupational etiology
EP1-05 Epidemiology of infectious agents
EP1-06 Radiation exposure and cancer risk
EP1-07 Other

Genetic Predisposition to Cancer
EP2-01 Genetic epidemiology/susceptibility
EP2-02 Molecular epidemiology
EP2-03 Risk assessment
EP2-04 Other
Prevention and Dietary Factors
EP3-01 Biological and biochemical mechanisms in prevention
EP3-02 Biomarkers and intervention studies
EP3-03 Chemoprevention
EP3-04 Diet and nutrition
EP3-05 Hormones and chemoprevention
EP3-06 Modulators of arachidonic acid metabolism
EP3-07 Molecular studies in prevention
EP3-08 Other

EXPERIMENTAL THERAPEUTICS
Drug Design, Screening, and Delivery
ET1-01 Biochemical modulators of the therapeutic index and toxicity
ET1-02 Combination chemotherapy
ET1-03 Drug design
ET1-04 Drug screening
ET1-05 Novel drug delivery systems
ET1-06 Other

Drug Resistance
ET2-01 Glutathione metabolism
ET2-02 Multidrug resistance
ET2-03 Natural products, synthetic drugs, and nucleotide analogs
ET2-04 Novel mechanisms
ET2-05 P-glycoprotein
ET2-06 Reversal of drug resistance
ET2-07 Other

Gene Therapy
ET3-01 Gene therapy

Mechanisms of Drug Action,
Pharmacokinetics, Pharmacodynamics, DNA Repair
ET4-01 Mechanisms of drug action
ET4-02 Mechanisms of DNA repair
ET4-03 Pharmacokinetics, pharmacodynamics, and cellular pharmacology
ET4-04 Toxicology

Therapeutic Agents I ("small" molecules)
ET5-01 Alkylating agents
ET5-02 Antifolates
ET5-03 Chemopreventive therapeutic agents
ET5-04 Ether lipids and their antitumor properties
ET5-05 Novel antitumor agents
ET5-06 Platinum complexes
ET5-07 Purine and pyrimidine antagonists
ET5-08 Other

Therapeutic Agents II (genes, gene components, antireceptors)
ET6-01 Antireceptors
ET6-02 Antisense oligonucleotides
ET6-03 Antiviral therapy
ET6-04 Apoptosis: therapy and mechanisms
ET6-05 Growth factor receptors and other surface antigens as targets for therapy

Therapeutic Agents II (genes, gene components, antireceptors) (cont.)
ET6-06 Oncogenes, tumor suppressor genes, and gene products as targets for therapy
ET6-07 Protein kinases and phosphatases as targets for therapy
ET6-08 Other

Topoisomerases, Other DNA Reactive Agents, and Tubulin Agents
ET7-01 DNA reactive agents
ET7-02 Topoisomerases
ET7-03 Tubulin agents

IMMUNOLOGY/BIOLOGICAL THERAPY
Immunobiology
IM1-01 Animal models for tumor immunology
IM1-02 Antigenic modulation
IM1-03 Immunodeficiency/immunosuppression
IM1-04 Immunomodulation
IM1-05 Integrins and cell adhesion molecules
IM1-06 Lymphokines/cytokines
IM1-07 Non specific effector mechanisms
IM1-08 Specific immunomechanisms
IM1-09 Tumor antigens

Preclinical and Clinical Immunotherapy
IM2-01 Antibodies/immunoconjugates
IM2-02 Cancer vaccines
IM2-03 Cellular immunotherapy
IM2-04 Cytokines
IM2-05 Immunodiagnostics
IM2-06 Immunotherapy of human cancer
IM2-07 Other

MOLECULAR BIOLOGY/BIOCHEMISTRY
Biochemistry
MB1-01 Cell surface receptors and the extracellular matrix
MB1-02 Enzymes and isoenzymes
MB1-03 Lipid metabolism
MB1-04 Membrane transport and function
MB1-05 Nucleotide, nucleic acid, and protein metabolism
MB1-06 Protein-DNA interactions
MB1-07 Retinoids and differentiation
MB1-08 Signal transduction

Gene Regulation
MB2-01 Antisense nucleic acids
MB2-02 Cell growth and differentiation
MB2-03 Cloning and mapping of genes and loci
MB2-04 Gene expression
MB2-05 Gene regulation
MB2-06 Transcription factors
MB2-07 Transgenic mice as models
MB2-08 Other

Genomic Alterations, Instability, and Repair
MB3-01 DNA methylation
MB3-02 Gene amplification
MB3-03 Genetic imprinting
MB3-04 Genomic instability
MB3-05 Loss of heterozygosity in neoplasia
MB3-06 Mechanisms of DNA damage and repair
MB3-07 Molecular cytogenetics
MB3-08 Radiation effects
MB3-09 Telomeres and telomeras

Oncogenes and Tumor Suppressor Genes, Viral Oncogenesis
MB4-01 Human tumor viruses
MB4-02 Molecular biology of viruses
MB4-03 Oncogenes and cancer progression, diagnosis, or prognosis
MB4-04 Oncogenes and development
MB4-05 Oncogenes and regulatory interactions
MB4-06 RNA and DNA tumor viruses
MB4-07 Tumor suppressor genes
MB4-08 Viral transformation
MB4-09 Other

RADIOBIOLOGY/RADIATION ONCOLOGY
RR1-01 Bioreductive drugs and radiation oncology
RR1-02 Cell cycle, differentiation, and apoptosis in radiation responses
RR1-03 Cytogenetics
RR1-04 Effects of radiation on membranes
RR1-05 Experimental radiotherapeutics
RR1-06 Genetic and epigenetic control of radiosensitivity
RR1-07 Hyperthermia
RR1-08 Modification of radiation sensitivity and injury
RR1-09 Molecular mechanisms/radiation-induced gene expression
RR1-10 Photobiology
RR1-11 Photodynamic therapy
RR1-12 Predictive assays for radiation sensitivity
RR1-13 Radiation and oncogenes/tumor suppressor genes
RR1-14 Radiation-drug interactions
RR1-15 Radiation-induced DNA damage, mutagenesis, and repair
RR1-16 Radiation-induced late effects
RR1-17 Radiation-induced transformation and carcinogenesis
RR1-18 Radiation resistance
RR1-19 Radiolabelled antibodies in diagnosis and localization
RR1-20 Radioprotectors and radiosensitizers
RR1-21 Tumor oxygenation and modification
RR1-22 Other
Antitumorigenic effects of a recombinant adenovirus containing the MYC antagonist MAD. Chen, J., Willingham, T., DePinho, R.*, Nisen, P.D. Univ. Texas Southwestern Med. Ctr., Dallas, TX 75235 and *Albert Einstein College of Medicine, Bronx, NY.

An adenovirus vector was used to transfer the MAD gene (Ad-MAD), an antagonist of MYC-family oncogenes, into the U373MG human astrocytoma cell line. Adenovirus:β-galactosidase (AdβGal) was used to demonstrate 90-100% infectivity and expression. [3H]thymidine incorporation in AdMAD cells was decreased by 80%. The rate of cell division was 46hr (versus 29hr for AdβGal cells). Cell cycle distribution was altered: 32% of AdMAD cells were in G1, versus 21% for AdβGal cells. There was no effect on apoptosis. Focus formation in soft agar was dramatically inhibited in AdMAD cells. Tumor formation in nude mice readily occurred using AdβGal cells but no tumors were observed if cells were infected with AdMAD. These studies indicate that adenovirus constructs containing MAD dramatically inhibit proliferation and tumorigenicity of a human astrocytoma cell line and supports the use of this construct for gene therapy.
1. Category and Subclassification
(see Pages 10-11): Type the five-character code in the blocks provided. For example.

| B | L | I | 0 | 1 |

Type abstract within blue lines. See sample abstract.

2. Abstract is SPONSORED by: _________________________ Member No. (See Directory of Members for Member No.)

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein. I also transfer copyright of this abstract to the American Association for Cancer Research, Inc. for reproduction in both printed and electronic media.

Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 6.)

Signature  Member No.

6. Abstract is to be PRESENTED by: _________________________ Member No. (If an AACR Member.)

7. Eligibility for Travel Awards

☐ A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.

☐ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).

8. As the PRESENTER of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1996 Annual Meeting and to collect all revenue from subsequent audiocassette sales.

Signature of PRESENTER


☐ MasterCard  ☐ VISA  ☐ Eurocard  ☐ American Express

Card No.  Expiration Date

Please verify that you have adhered to all AACR abstract submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including abstracts submitted without the required signatures, will result in a fee of US$35 which will be billed to the SPONSOR.
1. Category and Subclassification
(see Pages 10-11): Type the five-character code in the blocks provided, for example.

B L 1 - 0 1

2. Abstract is SPONSORED by: ____________Member No.  
(See Directory of Members for Member No.)

Name
(Please Print)
Address

City, State
Postal Code
Country

Telephone No.
FAX No.
E-Mail Address

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein. I also transfer copyright of this abstract to the American Association for Cancer Research, Inc. for reproduction in both printed and electronic media.

Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 6.)

Name
(Please Print)
Signature
Member No.

5. Identification of Financial Interests
☐ One or more of the authors of this abstract has a financial interest (see instructions) in products or processes involved in the research described. (If the box is checked, describe the financial interest(s) on a separate sheet).

6. Abstract is to be PRESENTED by: ____________Member No.  
(If an AACR Member.)

Name
(Please Print)
Address

City, State
Postal Code
Country

Telephone No.
FAX No.
E-Mail Address

7. Eligibility for Travel Awards
☐ A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.
☐ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).

8. As the PRESENTER of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1996 Annual Meeting and to collect all revenue from subsequent audiocassette sales.

Signature of PRESENTER

☐ MasterCard ☐ VISA ☐ Eurocard ☐ American Express

Card No. Expiration Date

Cardholder Name (PRINT) Signature

Please verify that you have adhered to all AACR abstract submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including abstracts submitted without the required signatures, will result in a fee of US$35 which will be billed to the SPONSOR.
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focused meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>in AACR Office</td>
<td></td>
</tr>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. OR—The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). OR—The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are $160, $95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates. Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
**APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP**

**NAME OF CANDIDATE:**

**LAST**

**FIRST**

**M.I.**

**DATE OF BIRTH:**

**PRESENT POSITION/TITLE:**

**INSTITUTIONAL AFFILIATION:**

**INSTITUTIONAL ADDRESS:**

(City)  
(State/Province)  
(Country)  
(Postal Code)

**TELEPHONE NUMBER:**

**FAX NUMBER:**

**E-MAIL NUMBER (CARRIER):**

**PRIMARY FIELD OF RESEARCH** (Please check only one):

- Biochemistry and Biophysics
- Biostatistics
- Carcinogenesis
- Cellular Biology and Genetics
- Clinical Investigations
- Endocrinology
- Epidemiology
- Immunology
- Molecular Biology and Genetics
- Preclinical Pharmacology and Experimental Therapeutics
- Virology
- Other: ____________________________ (Please specify)

**ACADEMIC DEGREES** (Including where and when granted)

**EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED** (Please list most recent first)

**PUBLICATIONS** (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

---

**CANDIDATE NOMINATED BY**: ____________________________  
(Please print)

**CANDIDATE SECONDED BY**: ____________________________  
(Please print)

**CANDIDATE IS APPLYING FOR** (Check one):  
☐ ACTIVE  
☐ CORRESPONDING  
MEMBERSHIP

**STATEMENT OF SUPPORT**

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? _____ years

Will the candidate make a long-term contribution to cancer research?  
☐ Yes  
☐ No

Does the candidate's research adhere to accepted ethical standards?  
☐ Yes  
☐ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

**Signature of nominator** ____________________________  
Date ____________________________

**Signature of seconder** ____________________________  
Date ____________________________

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.*

(This form may be reproduced.)  
8/95
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $35 or $45 dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1995 and 1996 have been set at $35 per year for residents of the Americas and $45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ________________________________

LAST FIRST M.I. DATE OF BIRTH: __________________

INSTITUTIONAL AFFILIATION: ________________________________

INSTITUTIONAL ADDRESS: ________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ________________________________ FAX NUMBER: ________________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): ______Graduate Student ______Medical Student

______Physician in Training ______Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

______Biochemistry and Biophysics ______Bionanotechnology ______Carcinogenesis

______Cellular Biology and Genetics ______Clinical Investigations ______Endocrinology

______Epidemiology ______Immunology ______Molecular Biology and Genetics

______Preclinical Pharmacology and ______Virology ______Other: ________________________________

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

CANDIDATE NOMINATED BY: ________________________________

(Please type or print name of AACR active member* in good standing.)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ________________________________ Date: __________________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ________________________________ Date: __________________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the ☐ current ☐ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

* Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)

8/95

20s
AMERICAN ASSOCIATION FOR CANCER RESEARCH
1996 EMPLOYMENT REGISTER FORMS AND INSTRUCTIONS

INTRODUCTION

The AARC's Employment Register is intended to attract young scientists to the Association, increase interest in AARC programs, and provide a valuable service to all cancer researchers, both senior and junior investigators.

Since 1988, AARC Staff has scheduled interviews at the annual meeting, and brief advertisements describing available candidates and positions have been published in the Proceedings of the American Association for Cancer Research and in three issues of Cancer Research. These services will be continued in 1996. Registration forms for the 1996 Employment Register can be found on the following pages. Fees have been set at the following levels:

Each candidate registration
- by an AARC member $10
- by a nonmember $25

Each position listing
- by an AARC member from a nonprofit or governmental organization $75
- by a nonmember from a nonprofit or governmental organization $125
- by a commercial organization $275
  ($225 for companies participating in the 1996 AARC Exhibit Show)

INSTRUCTIONS FOR CANDIDATES

1. Supply all information requested on the attached candidate registration form.
2. Type a short description of your background and the position you are seeking in the 5" X 1 1/4" box provided. Do not include your name; the AARC will assign identification numbers to all candidate listings. Please type carefully; this description will be reproduced as described in the section below entitled PUBLICATION OF LISTINGS.
3. Enclose the original form plus 1 copy.
4. Enclose appropriate payment:
   a. $10 from AARC members
   b. $25 from nonmembers
5. Checks should be issued in U.S. dollars, drawn on a U.S. bank, and made payable to AARC, Inc.
6. Forms should be submitted by January 8, 1996, to ensure publication of listings in the Proceedings. However, candidate registration forms will continue to be accepted in the Association Office until March 29, 1996. After that date forms should be submitted at the annual meeting.
7. Mail all candidate registration forms to:
   Employment Register
   American Association for Cancer Research, Inc.
   Public Ledger Building, Suite 816
   150 S. Independence Mall West
   Philadelphia, PA 19106-3483

INSTRUCTIONS FOR EMPLOYERS

1. Complete a separate position listing form for each position available and supply all information requested.
2. Type a short description of the position available in the 5" X 1 1/4" box provided. Please type carefully; this description will be reproduced as described in the section below entitled PUBLICATION OF LISTINGS.
3. Enclose the original form plus 1 copy.
4. Enclose appropriate payment for each position listed:
   a. $75 from AARC members in nonprofit or governmental organizations,
   b. $125 from nonmembers in nonprofit or governmental organizations,
   c. $275 from commercial firms ($225 from firms participating in the 1996 AARC Exhibit Show).

SCHEDULING OF INTERVIEWS

The AARC will set aside space at the annual meeting for interviews which will be scheduled at mutually agreeable times during the following hours: Saturday, April 20, from 1:00-7:00 p.m.; Sunday, Monday, and Tuesday, April 21-23, from 8:00 a.m. to 5:00 p.m.; and Wednesday, April 24, from 9:00 a.m. to 1:00 p.m. Each candidate and employer will receive an identification number. Registrants who submit their forms and fees by March 29, 1996, will receive an acknowledgment card which contains their identification number.

PUBLICATION OF LISTINGS

Short advertisements describing each candidate and position listing will be published in Volume 37 (1996) of the Proceedings of the American Association for Cancer Research and in the July 1, September 1, and November 1, 1996, issues of Cancer Research. The attached forms contain space for copy for these advertisements. Please type carefully to ensure accurate reproduction of your advertisement. Your copy must not exceed the limits of the box because space for these advertisements is limited. Advertisements for available positions should contain the name and address of the person conducting the job search, and candidates will be able to communicate with that person directly. Candidate advertisements will be anonymous. The AARC will send the candidate's complete form via first-class mail to any registered employer who requests it. The employer must bear the cost of receiving candidate forms in any manner other than first-class mail.

As noted above, because of the early publication date of the Proceedings, forms must be received by January 8, 1996, to ensure publication in that document. However, all advertisements submitted before or during the meeting will be published in the three issues of Cancer Research. Registrants wishing to withdraw their advertisements must submit written requests to that effect to the Association Office by May 15, 1996, for the July 1 issue; July 15, 1996, for the September 1 issue; and September 16, 1996, for the November 1 issue. All participants in the Employment Register are urged to notify the Association immediately of any change in their status so that all listings will remain current.

FURTHER INFORMATION

Questions about the Employment Register may be directed to the Association Office at 215-440-9300.
DESCRIPTION OF POSITION

Title

Nature of Work and Responsibilities (research, teaching, administration, etc.)

Education and Experience Required

Date Position Available__________________________  Annual Salary Range__________________________

Location of Position

Areas of Specialization
(Indicate a maximum of three in order of greatest activity)

2. Endocrinology  3. Epidemiology  4. Experimental Therapeutics  5. Immunology
4. Virology  6. Other (please specify):

EMPLOYER’S REPRESENTATIVE(S)

Name(s) and Title(s)

Institution

Address

Telephone

AVAILABILITY FOR INTERVIEWS AT AACR ANNUAL MEETING

I ___ plan ___ do not plan to attend the AACR Annual Meeting in Washington, DC.

Dates available for interviews: ___ April 20 ___ April 21 ___ April 22 ___ April 23 ___ April 24

ADVERTISEMENT (Please type a short description of the position in the box below. If received by January 8, 1996, your advertisement will be printed in the 1996 Proceedings. All advertisements will appear in the July 1, September 1, and November 1, 1996, issues of Cancer Research.)


(This form may be reproduced)
### CANDIDATE REGISTRATION

**AMERICAN ASSOCIATION FOR CANCER RESEARCH EMPLOYMENT REGISTER**

(Please type and submit original and 1 copy plus payment)

#### TYPE OF POSITION DESIRED
(Check all that apply)

- [ ] Postdoctoral
- [ ] Physician in Training
- [ ] Research Associate/Staff Scientist
- [ ] Faculty

#### TYPE OF INSTITUTION DESIRED
(Check all that apply)

- [ ] Industry
- [ ] Academic
- [ ] Government

<table>
<thead>
<tr>
<th>Name: ____________________________</th>
<th>Last</th>
<th>First</th>
<th>M.I.</th>
<th>AACR Member Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business Mailing Address: __________</td>
<td>_______</td>
<td>_______</td>
<td>_______</td>
<td>____________________</td>
</tr>
<tr>
<td>_________________________________________________________________________</td>
<td>_______</td>
<td>_______</td>
<td>_______</td>
<td>____________________</td>
</tr>
<tr>
<td>Major Field: ______________________________________________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highest Degree: ____________________________________________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year Obtained: ___________________________________________________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bus. Telephone : ____________________</th>
<th>Citizenship: ________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of Visa: ______________________</td>
<td>Desired Salary: _____________________</td>
</tr>
<tr>
<td>Date Available: ____________________</td>
<td>Geographic Preference: ________________</td>
</tr>
</tbody>
</table>

### Areas of Specialization

(Indicate a maximum of three in order of greatest activity)

- [ ] Biochemistry & Biophysics
- [ ] Cancerogenesis
- [ ] Cellular Biology & Genetics
- [ ] Clinical Investigations
- [ ] Endocrinology
- [ ] Epidemiology
- [ ] Experimental Therapeutics
- [ ] Immunology
- [ ] Molecular Biology & Genetics
- [ ] Prevention
- [ ] Radiobiology/Radiation Oncology
- [ ] Virology
- [ ] Other (please specify): __________

#### ADVERTISEMENT
(Please type a short description of your background and the position you are seeking in the box below. If received by January 8, 1996, your advertisement will be printed in the 1996 Proceedings. All advertisements will appear in the July 1, September 1, and November 1, 1996, issues of Cancer Research. DO NOT GIVE YOUR NAME OR ADDRESS; the AACR will assign identification numbers to each advertisement.)

Name_____________________________________________________________  Candidate I.D. Number___________________

ACADEMIC TRAINING
College or University  From/To  Major  Minor  Degree(s)
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

POSITIONS HELD (List in chronological order, current position first)
Employer  From/To  Position/Nature of Duties
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

PUBLICATIONS (List five most recent; include titles and co-authors)
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

OTHER (List specific areas of expertise, professional societies, honors, etc.)
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

REFERENCES (Give name and business address)
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

AVAILABILITY FOR INTERVIEWS AT AACR ANNUAL MEETING
I ______plan ______do not plan to attend the AACR Annual Meeting in Washington, DC.
Dates available for interviews: _____April 20  _____April 21  _____April 22  _____April 23  _____April 24

(This form may be reproduced)
General Information
Please read this page before calling the Washington Convention and Visitors Association (WCVA) Housing Service.

Deposits
A $125.00 per room deposit is required, payable by credit card or check.

- **Credit card** - Your credit card will be charged immediately. Most major credit cards are accepted. Your room confirmation will be sent upon acceptance of your credit card charge.

- **Check** - An invoice for the $125.00 per room deposit will be mailed to you. Payment must be received within 15 days of the invoice date or your reservation will be cancelled. Do not send payment without an invoice stub. Your room confirmation will be sent upon receipt of check.

Changes
- Prior to March 21, 1996, all changes should be made with the WCVA Housing Service. After March 21, changes should be made with the hotel.

Cancellations/Refunds
- Cancellations made prior to March 21, 1996 should be made with the WCVA Housing Service and will be refunded in full. The WCVA Housing Service will issue the refund.

- Cancellations made after March 21, and prior to 72 hours of arrival should be made with the hotel. A $10.00 service fee will be deducted from your deposit. The hotel will issue the refund.

Instructions
Call the WCVA Housing Service, Monday through Friday, from 9:00 a.m. to 5:00 p.m. Eastern Time. The hotels will not accept reservations directly.

- Conferences in the United States and Canada -- call **1-800-535-3336**.

- Conferences in the Washington, D.C., area and International Conferences -- call **202-842-2930**.

- International Conferences **ONLY** -- FAX **202-289-8079**.

Tell the WCVA Housing Service operator you are calling for the AACR Annual Meeting hotel reservations. Please have the following information ready:

1. Hotel preference (1st, 2nd, and 3rd choices)
2. Arrival and departure dates and times (indicate arrival after 6:00 p.m.)
3. Number of rooms required
4. Accommodations desired
   - Single
   - Double (1 bed, 2 people)
   - Twin (2 beds, 2 people)
   - Triple
   - Quad (2 double beds, 4 people)
   - Suite
5. Number of people in party
6. Credit card name, account number, name as it appears on card, and expiration date
7. Names of all occupants of room(s)
8. Address
9. Daytime telephone number with area code
10. FAX number with area code
11. Special requests (disability, smoking/nonsmoking, king-size bed, etc.)

Inquiries
Washington Convention & Visitors Association
Housing Service
1212 New York Avenue, N.W.
Washington, D.C. 20005-3992
### HOTELS IN WASHINGTON, D.C.
#### RESERVING ROOMS FOR AACR REGISTRANTS

<table>
<thead>
<tr>
<th>MAP NUMBER</th>
<th>HOTEL NAME</th>
<th>SINGLE</th>
<th>DOUBLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Grand Hyatt Washington*</td>
<td>$168</td>
<td>$188</td>
</tr>
<tr>
<td>2</td>
<td>Renaissance Washington, D.C. Hotel*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Main Hotel</td>
<td>$154</td>
<td>$174</td>
</tr>
<tr>
<td></td>
<td>Renaissance Club - Tower</td>
<td>$174</td>
<td>$194</td>
</tr>
<tr>
<td>3</td>
<td>The Bellevue Hotel</td>
<td>$109</td>
<td>$124</td>
</tr>
<tr>
<td>4</td>
<td>The Capital Hilton</td>
<td>$179</td>
<td>$199</td>
</tr>
<tr>
<td>5</td>
<td>The Comfort Inn</td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>6</td>
<td>Days Inn Downtown</td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>7</td>
<td>The Henley Park Hotel</td>
<td>$157</td>
<td>$177</td>
</tr>
<tr>
<td>8</td>
<td>Holiday Inn Central</td>
<td>$105</td>
<td>$105</td>
</tr>
<tr>
<td>9</td>
<td>Holiday Inn Franklin Square</td>
<td>$105</td>
<td>$105</td>
</tr>
<tr>
<td>10</td>
<td>Holiday Inn on the Hill</td>
<td>$129</td>
<td>$139</td>
</tr>
<tr>
<td>11</td>
<td>Hotel Washington</td>
<td>$150</td>
<td>$150</td>
</tr>
<tr>
<td>12</td>
<td>Marriott at Metro Center</td>
<td>$159</td>
<td>$159</td>
</tr>
<tr>
<td>13</td>
<td>Phoenix Park</td>
<td>$150</td>
<td>$170</td>
</tr>
<tr>
<td>14</td>
<td>Stouffer Renaissance Mayflower Hotel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$169</td>
<td></td>
<td>$199</td>
</tr>
<tr>
<td>15</td>
<td>The Washington Court</td>
<td>$160</td>
<td>$160</td>
</tr>
<tr>
<td>16</td>
<td>The Washington Vista</td>
<td>$155</td>
<td>$165</td>
</tr>
</tbody>
</table>

*Co-Headquarters

---

ALL RATES ARE SUBJECT TO A 13% DISTRICT OF COLUMBIA TAX AND A $1.50 OCCUPANCY TAX PER ROOM PER NIGHT.
MAP OF WASHINGTON, D.C. SHOWING HOTELS RESERVING ROOMS FOR AACR REGISTRANTS
AMERICAN ASSOCIATION FOR CANCER RESEARCH

1995-1996 TRAVEL AWARDS FOR YOUNG INVESTIGATORS

Supported in part by AACR, WICR, The Gerald B. Grindev Memorial Fund, and the Comprehensive Minority Biomedical Program of the NCI; Additional Sponsors to be Announced

• Corporate- and AACR-sponsored Travel Awards are offered to the AACR Annual Meeting for medical and graduate students, physicians in training, and postdoctoral fellows who are presenters of abstracts that have been highly rated by the Program Committee. For further information, consult the Call for Abstracts, sent each Fall to all AACR members and nonmembers who request it.

• In 1996, the AACR will also offer the first Gerald B. Grindevy Memorial Travel Award to the Annual Meeting for a particularly deserving young scientist submitting an abstract in the field of preclinical science.

• Travel Awards are offered to the Annual Meeting and AACR Special Conferences through the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI). Those eligible for these awards are graduate and medical students, physicians in training, and postdoctoral students from minority groups considered underrepresented in cancer research by the NCI, i.e., African Americans, Hispanic Americans, Native Americans, Native Pacific Islanders, and Alaskan Americans. Please call the AACR for an application form.

• WICR Student/Trainee Travel Awards are available for graduate and medical students, physicians in training, and postdoctoral fellows who have submitted an abstract for the Annual Meeting and have been nominated by a member in good standing of Women in Cancer Research (WICR). For further information please call Dr. Mary Jean Sawey at (215) 898-0270.

• Travel Awards are also available for a limited number of young scientists attending each of the AACR's Special Conferences. For details, consult the conference brochure for each meeting, available on request from the AACR office.

Young scientists may also wish to obtain information about other relevant AACR programs including research fellowships, the Employment Register, Mentorship Program for young minority investigators, and educational programs at the Annual Meeting and throughout the year.

For Further Information:

AMERICAN ASSOCIATION FOR CANCER RESEARCH

Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313/e-mail: aacr@aol.com
86th Annual Meeting • American Association for Cancer Research

Programs consist of either 1 tape/$11.50, 2 tapes/$23.00, or 3 tapes/$34.50 (prices indicated before each title)

Circle the number of each title you want to order, and return this form to:

Cancer Research, 10707 North Oregon Road, Columbus, OH 43220-1998

AUDIO CASSETTE ORDER FORM

Your invoice will be sent to you. (Continental US only). Any purchases over $50.00 ship FREE. For faster service, call:

1-800-824-4248

AUDIO CASSETTE DISCOUNTS

1-5 cassettes ........................................ $11.50
6-11 cassettes ........................................ 9% DISCOUNT
12-24 cassettes ....................................... 10% DISCOUNT
25-48 cassettes ....................................... 15% DISCOUNT
49 + ...................................................... 20% DISCOUNT

Programs consist of 1, 2, or 3 cassettes. Prices are listed after each program title.

☐ CAN 501 (3 cass, $34.50) Methods Workshop 1: General, in Situ, and Quantitative PCR
☐ CAN 502 (3 cass, $34.50) Methods Workshop 2: Gene Targeting and Gene Trapping in Mice
☐ CAN 503 (2 cass, $23.00) Educational Session 1: Molecular Modelling to Medical Monitoring: The Development of New Anticancer Agents
☐ CAN 504 (2 cass, $23.00) Educational Session 2: Gene Therapy
☐ CAN 505 (2 cass, $23.00) Educational Session 3: Genetic Instability in Cancer
☐ CAN 506 (2 cass, $23.00) Educational Session 4: Cytochrome C450
☐ CAN 507 (1 cass, $11.50) Meet the Expert Sunrise Session: Pediatric Oncology, Joseph V. Simone
☐ CAN 508 (1 cass, $11.50) Meet the Expert Sunrise Session: A Primer on Analyzing Clinical Trials, Steven Plantadit
☐ CAN 509 (1 cass, $11.50) Meet the Expert Sunrise Session: Farnesyltransferase as a Target for Therapy, Alexander W. Wood
☐ CAN 510 (1 cass, $11.50) Meet the Expert Sunrise Session: P-Glycoprotein Biology and Multidrug Resistance, Victor Ling
☐ CAN 511 (1 cass, $11.50) Meet the Expert Sunrise Session: Is a Mutagenic Event Involved in Initiation? Ann R. Kennedy
☐ CAN 512 (3 cass, $34.50) Minisymposium Immunology/Biological Therapy 1: Tumor Immunogenicity and Effector Cells
☐ CAN 513 (3 cass, $34.50) Minisymposium Carcinogenesis 1: Detection of Carcinogen-DNA Adducts in Humans
☐ CAN 514 (3 cass, $34.50) Minisymposium Experimental Therapeutics 1: Molecular Studies of Selected Agents
☐ CAN 515 (3 cass, $34.50) Minisymposium Organ Site/Translational Session 1: Molecular and Cellular Aspects of Gynecological Malignancies
☐ CAN 516 (3 cass, $34.50) Minisymposium Molecular Biology/Biochemistry 1: New Tumor Suppressor Genes
☐ CAN 517 (2 cass, $23.00) Plenary Session: Integrated View of the Cancer Cell
☐ CAN 519 (1 cass, $11.50) Controversy Session 1: Breast Cancer Prevention: What Will We Advise Women With BRCA1?
☐ CAN 520 (3 cass, $34.50) Minisymposium Clinical Investigations 2: Tumor Vaccine and Cyclotytic T-Cell Generation
☐ CAN 521 (3 cass, $34.50) Minisymposium Molecular Biology/Biochemistry 4: Retinoids and Their Receptors
☐ CAN 522 (3 cass, $34.50) Minisymposium Experimental Therapeutics 6: Molecular Studies of Folates
☐ CAN 523 (3 cass, $34.50) Minisymposium Biology 4: Advances in Invasion, Metastasis, and Angiogenesis Research
☐ CAN 524 (2 cass, $23.00) Symposium 1: Growth Factors, Their Receptors, and Differentiation
☐ CAN 525 (2 cass, $23.00) Symposium 2: Oligonucleotide-mediated Modulation of Mammalian Gene Expression
☐ CAN 526 (2 cass, $23.00) Symposium 3: Biomarkers of Carcinogenesis
☐ CAN 527 (2 cass, $23.00) Symposium 4: DNA Repair Pathways: Recent Surprises
☐ CAN 528 (2 cass, $23.00) Symposium 5: Mechanistic Basis of Ethnic Differences in Cancer Risk
☐ CAN 529 (1 cass, $11.50) Presidential Address: There’s More Than One Way to Skin a Cat or Regulation of the Polyyclic Hydrocarbon-inducible Cytochrome P450IA1 Gene, Edward Bresnick: Presentation of the Third Gertrude Elion Cancer Research Award
☐ CAN 530 (2 cass, $23.00) Careers and Opportunities in Cancer Research: Models for Success: A Symposium Organized by the Committee on Minority Issues
☐ CAN 531 (1 cass, $11.50) Meet the Expert Sunrise Session: Everything You Always Wanted to Know About Prostatic Cancer But Were Afraid to Ask, John T. Isaacs
☐ CAN 532 (1 cass, $11.50) Meet the Expert Sunrise Session: Colon Cancer, Ronald N. Buick
☐ CAN 533 (1 cass, $11.50) Meet the Expert Sunrise Session: Peripheral Blood Progenitor Cell Transplantation, Elizabeth J. Shpall
☐ CAN 534 (1 cass, $11.50) Meet the Expert Sunrise Session: Multivariate Determinants of Radiocurability: Predictive Assays in Radiation Oncology, Richard P. Hill

☐ CAN 535 (1 cass, $11.50) Meet the Expert Sunrise Session: Glutathione and Associated Enzymes in Anticancer Drug Response, Kenneth D. Tew
☐ CAN 536 (3 cass, $34.50) Symposium 6: Genetic Susceptibility to Cancer
☐ CAN 537 (2 cass, $23.00) Symposium 7: Combinatorial Libraries for Cancer Research and Drug Discovery
☐ CAN 538 (2 cass, $23.00) Symposium 8: Telomeres and Telomeras
☐ CAN 539 (2 cass, $23.00) Symposium 9: Immunotherapy: Tumor Vaccines
☐ CAN 540 (2 cass, $23.00) Symposium 10: Glycosylation Defining Malignancy
☐ CAN 541 (3 cass, $34.50) Minisymposium Radiobiology/Radiation Oncology 2: Radiation-Induced Gene Expression
☐ CAN 542 (3 cass, $34.50) Minisymposium Clinical Investigations 4: New Drugs: Phase I Studies
☐ CAN 543 (3 cass, $34.50) Minisymposium Experimental Therapeutics 12: Transcriptional/Translational Control of Drug Resistance Genes
☐ CAN 544 (3 cass, $34.50) Minisymposium Biology 8: Signal Transduction II
☐ CAN 545 (1 cass, $11.50) Controversy Session 2: Does the Current Body of Doxin Pose a Risk to the Health of the North American Population?
☐ CAN 546 (1 cass, $11.50) Fourth American Cancer Society Award Lecture: Inherited Susceptibility to Cancer: From Epidemiology to Interventional Research, Frederick J. F. L. Gill
☐ CAN 548 (1 cass, $11.50) Controversy Session 3: What Are the Benefits and Limits of Prostate-specific Antigen as a Screening Tool?
☐ CAN 549 (3 cass, $34.50) Minisymposium Carcinogenesis 11: Carcinogen Activation in Humans
☐ CAN 550 (2 cass, $34.50) Minisymposium Molecular Biology/Biochemistry 10: Signal Transduction and Tumorigenesis
☐ CAN 551 (3 cass, $34.50) Minisymposium Experimental Therapeutics 18: Targeting Topoisomerases I
☐ CAN 552 (3 cass, $34.50) Minisymposium Organ Site/Translational Session 4: Oncogenes, Tumor Suppressor Genes, and Growth Factors in Breast Cancer
☐ CAN 553 (3 cass, $34.50) Minisymposium Biology 11: Apoptosis III
☐ CAN 554 (2 cass, $23.00) Symposium 11: New Strategies and Targets for Therapy of Cancer
☐ CAN 555 (2 cass, $23.00) Symposium 12: The Biology of Radiation Oncology
☐ CAN 557 (2 cass, $23.00) Symposium 13: Genes, Development, and Cancer
☐ CAN 558 (2 cass, $23.00) Symposium 14: Dietary Intervention in Hormonal Carcinogenesis
☐ CAN 559 (2 cass, $23.00) AACR Annual Business Meeting
☐ CAN 560 (1 cass, $11.50) Meet the Expert Sunrise Session: Human Gene Therapy in Urological Oncology, Jonathan W. Simon
☐ CAN 561 (1 cass, $11.50) Meet the Expert Sunrise Session: Chemical and Viral Epilogies of Liver Cancer: Application of Mechanistic Knowledge to Preventive Interventions, John D. Growman
☐ CAN 562 (1 cass, $11.50) Meet the Expert Sunrise Session: Biochemical Determinants of Carcinogenesis: The AH Receptor and Human Responses to Dioxins, Allan B. Okey
☐ CAN 563 (1 cass, $11.50) Meet the Expert Sunrise Session: Organ-specific Carcinogenesis (Location, Location, Location) Cheryl Lyn Walker
☐ CAN 565 (1 cass, $11.50) NIH Grants Session: Succeeding in a Changing Environment
☐ CAN 566 (2 cass, $23.00) Symposium 15: Translational Research in Breast Cancer
☐ CAN 567 (2 cass, $23.00) Symposium 16: DNA Methylation
☐ CAN 568 (2 cass, $23.00) Symposium 17: Genetic Approaches to Invasion and Metastasis
☐ CAN 569 (2 cass, $23.00) Symposium 18: The Role of Stromal-Epithelial Interactions in Growth and Neoplasia
☐ CAN 570 (3 cass, $34.50) Minisymposium Immunology/Biological Therapy 7: New Developments in Tumor Immunobiology
☐ CAN 571 (3 cass, $34.50) Minisymposium Epidemiology 3: Carcinogen Metabolism and Biomarkers
☐ CAN 572 (3 cass, $34.50) Minisymposium Clinical Investigations 7: Experimental and Clinical Gene Therapy
☐ CAN 573 (3 cass, $34.50) Minisymposium Biology 15: Cell Cycle II
☐ CAN 574 (3 cass, $34.50) Minisymposium Experimental Therapeutics 24: Targeting ras
☐ CAN 575 (1 cass, $11.50) Controversy Session 4: Is Mammography Before Age 50 Beneficial?
☐ CAN 577 (1 cass, $11.50) Late-Breaking Research Session
☐ CAN 578 (3 cass, $34.50) Minisymposium Organ Site/Translational Session 6: Gastrointestinal Cancer: Susceptibility, Diagnosis, and Prognosis
THE FOLLOWING PROGRAMS ARE AVAILABLE ON VIDEO CASSETTE

EACH VIDEO PROGRAM CONSISTS OF
ONE VIDEO, $39.00 UNLESS OTHERWISE NOTED

- CAN 517V (2 cass, $34.50) Minisymposium Experimental Therapeutics 30: MRP and Other Novel Drug Resistance Genes and Mechanisms
- CAN 580 (2 cass, $34.50) Minisymposium Carcinogenesis 19: Cell Cycle Genes in Carcinogenesis
- CAN 581 (2 cass, $34.50) Minisymposium Biology 19: Moving Invasion, Metatasis, and Angiogenesis Research toward Clinical Applications
- CAN 582 (2 cass, $34.50) Minisymposium Molecular Biology/Biochemistry 16: Alterations of the Cancer Genome
- CAN 583 (2 cass, $23.00) Symposium 19: Contribution of Environmental Factors to Cancer
- CAN 584 (2 cass, $23.00) Symposium 20: Stem Cell Transplantation and High-Dose Chemotherapy
- CAN 585 (2 cass, $23.00) Symposium 21: Signal Transduction and Gene Control and Development
- CAN 586 (2 cass, $23.00) Symposium 22: Natural Products in Chemoprevention of Cancer
- CAN 587 (1 cass, $11.50) Fourteenth Cornelius P. Rhoads Memorial Award Lecture: Mapping Genes and Genomes: Genetic Dissection of Complex Traits, Eric S. Lander
- CAN 588 (1 cass, $11.50) Meet the Expert Sunrise Session: Pharmacokinetic/Pharmacodynamic Relationships in Cancer Chemotherapy, Merrill J. Egorin
- CAN 589 (1 cass, $11.50) Meet the Expert Sunrise Session: Cellular and Molecular Biology Underlying Relationships between the Major Forms of Human Lung Cancer, Stephen B. Baylin
- CAN 590 (1 cass, $11.50) Meet the Expert Sunrise Session: Prostate-specific Gene Expression in Transgenic Mice, Norman M. Greenberg
- CAN 591 (1 cass, $11.50) Meet the Expert Sunrise Session: Tyrosine Phosphorylation in Transcytotic Signaling, Tony Hunter
- CAN 592 (1 cass, $11.50) Meet the Expert Sunrise Session: Molecular Determinants of Multidrug Resistance: p53 Mutations Are Associated with Resistance of Hematopoietic Malignancies to Chemotherapy, Elizabeth W. Newcomb
- CAN 593 (2 cass, $23.00) Symposium 23: The Cell Cycle and Tumor Suppressor Genes
- CAN 594 (2 cass, $23.00) Symposium 24: Transcription Factors in Development and Neoplasia
- CAN 595 (2 cass, $23.00) Symposium 25: Human Gene Therapy in Clinical Cancer
- CAN 596 (2 cass, $23.00) Symposium 26: Graft versus Tumor Effects
- CAN 597 (2 cass, $34.50) Minisymposium Prevention 5: Chemoprevention: Inhibitors of the Arachidonic Acid Cascade
- CAN 598 (2 cass, $34.50) Minisymposium Endocrinology 5: Prostate Cancer II
- CAN 599 (2 cass, $34.50) Minisymposium Organ Site/Translational Session 7: Lung and Head and Neck Translational Research
- CAN 5100 (3 cass, $34.50) Minisymposium Experimental Therapeutics 36: Novel Agents
- CAN 5101 (3 cass, $34.50) Minisymposium Carcinogenesis 22: Human Genetics and Cancer Susceptibility
- CAN 5102 (1 cass, $11.50) Symposium 6: Is Bone Marrow Transplantation Indicated for Breast Cancer?
- CAN 5103 (1 cass, $11.50) Fourteenth Bruce F. Cain Memorial Award Lecture: Initiatives with Platinum- and Quinazoline-based Antitumor Molecules, Kenneth R. Harrap
- CAN 5104 (1 cass, $11.50) Symposium 6: Are Estrogens Implicated in Breast Cancer?
- CAN 5105 (3 cass, $34.50) Minisymposium Molecular Biology/Biochemistry 22: Regulation of Enzymes that Metabolize Drugs and Carcinogens
- CAN 5106 (3 cass, $34.50) Minisymposium Immunology/Biological Therapy 12: Immunological and Therapeutic Aspects of Central Nervous System Tumors
- CAN 5107 (3 cass, $34.50) Minisymposium Clinical Investigations 13: Hematopoietic Stem Cell Transplantation/High-Dose Chemotherapy
- CAN 5108 (3 cass, $34.50) Minisymposium Carcinogenesis 26: Signal Transduction, Growth Factors, and Cellular Communication
- CAN 5109 (3 cass, $34.50) Minisymposium Experimental Therapeutics 42: Drug Resistance: New Strategies and Targets
- CAN 5110 (2 cass, $23.00) Symposium 27: Angiogenic Control of Tumor Growth
- CAN 5111 (2 cass, $23.00) Symposium 28: Extracellular Matrix, Gene Expression and Cell Signalling
- CAN 5112 (2 cass, $23.00) Symposium 29: Apoptosis
- CAN 5113 (2 cass, $23.00) Symposium 30: Cancer Prevention and Intermediate Biomarkers

VIDEO CASSETTE DISCOUNT
Save 10% on entire set of videotapes

PLEASE COMPLETE AND RETURN ENTIRE FORM

<table>
<thead>
<tr>
<th>VIDEO ORDERS</th>
<th>CHECK ENCLOSED PAYABLE TO TEACH 'EM</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Please check one)</td>
<td></td>
</tr>
<tr>
<td>VHS</td>
<td></td>
</tr>
<tr>
<td>PAL ($15 conversion surcharge)</td>
<td></td>
</tr>
<tr>
<td>CHECK ENCLOSED PAYABLE TO TEACH 'EM</td>
<td></td>
</tr>
<tr>
<td>VISA</td>
<td>$25 MINIMUM ON CREDIT CARD ORDERS</td>
</tr>
<tr>
<td>MC</td>
<td>CARD #</td>
</tr>
<tr>
<td>AMEX</td>
<td>EXPIRATION DATE</td>
</tr>
</tbody>
</table>

SEND TO: TEACH 'RM, 160 EAST ILLINOIS ST., CHICAGO, IL 60611
PHONE: (312) 467-0244 • FAX: (312) 467-9271 • TOLL-FREE: 1-800-225-3775

NAME ________________________ TITLE ________________________
ORGANIZATION ________________________
ADDRESS (NO PO BOXES) ________________________ CITY ________________________ STATE _____ ZIP ______
SIGNATURE ________________________ TELEPHONE ( )

PLEASE NOTE: Any defective tapes will be replaced, but tapes are nonrefundable.

305
# ADVANCE REGISTRATION FORM

**AMERICAN ASSOCIATION FOR CANCER RESEARCH**  
**87TH ANNUAL MEETING - WASHINGTON, DC - April 20-24, 1996**

---

**Return to**  
American Association for Cancer Research  
Public Ledger Building, Suite 816  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
FAX: 215-440-7228

---

**DEADLINES:**  
- March 1, 1996 for reduced rates and to ensure receipt of meeting materials by mail in late March or early April  
- March 25, 1996 for all registration by mail (Registration forms received after this date will not be accepted. Registration will be conducted at the Washington Convention Center from April 20-24.)  
- April 17, 1996 to cancel registration and receive refund less cancellation fee ($35)

(Please print)

**NAME:**  
Last  
First/Middle Initial  
AACR Member Number

**TITLE:**  
ADDRESS:

Street, Building, or Post Office Box

City  
State or Province  
Zip/Postal Code  
Country (if not U.S.)

**TELEPHONE NO.:**  
FAX NO.:  

☐ Check this box if you have a physical disability and have special requirements for transportation, hotel accommodations, or other facilities in connection with the meeting. A member of the Association Staff will contact you.

**WHAT IS YOUR PRIMARY FIELD OF RESEARCH (Please check only one):**  
- Biochemistry and Biophysics  
- Carcinogenesis  
- Cellular Biology & Genetics  
- Clinical Investigations  
- Endocrinology  
- Epidemiology  
- Experimental Therapeutics  
- Immunology  
- Molecular Biology & Genetics  
- Prevention  
- Radiobiology/Radiation Oncology  
- Virology  
- Other (please specify):

**ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1996 AACR MEETING?**  
☐ Yes  
☐ No

**ON WHICH DAYS WILL YOU ATTEND THE 1996 AACR ANNUAL MEETING?**  
☐ Saturday, April 20  
☐ Sunday, April 21  
☐ Monday, April 22  
☐ Tuesday, April 23  
☐ Wednesday, April 24

---

**PAYMENT OF REGISTRATION**

Fees may be paid by check or with a MasterCard, VISA, American Express, or Eurocard account. All payments must be made in U.S. currency, and all checks must be drawn on a U.S. bank. Payment must accompany this form; purchase orders will not be accepted as payment.

<table>
<thead>
<tr>
<th>On or Before March 1</th>
<th>After March 1</th>
<th>METHOD OF PAYMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active/Corresponding Member Rate</td>
<td>$135</td>
<td>$170</td>
</tr>
<tr>
<td>Nonmember Rate</td>
<td>$270</td>
<td>$340</td>
</tr>
<tr>
<td>(includes copy of AACR Proceedings)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emeritus Member Rate</td>
<td>$75</td>
<td>$85</td>
</tr>
<tr>
<td>Associate Member Rate*</td>
<td>$50</td>
<td>$50</td>
</tr>
<tr>
<td>Predoctoral Student Rate*</td>
<td>$40</td>
<td>$40</td>
</tr>
<tr>
<td>Honorary Member Rate</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>AACR Proceedings*</td>
<td>$35 Members</td>
<td>$35 Members</td>
</tr>
<tr>
<td></td>
<td>$45 Nonmembers</td>
<td>$45 Nonmembers</td>
</tr>
<tr>
<td>Optional Overseas Surcharge*</td>
<td>$25</td>
<td>N.A.</td>
</tr>
<tr>
<td>Proceedings on CD-ROM</td>
<td>$35 Members</td>
<td>$35 Members</td>
</tr>
<tr>
<td></td>
<td>$45 Nonmembers</td>
<td>$45 Nonmembers</td>
</tr>
<tr>
<td>Methods Workshop Registration</td>
<td>$50</td>
<td>$50</td>
</tr>
<tr>
<td>TOTAL ENCLOSED OR CHARGED</td>
<td>$</td>
<td>$</td>
</tr>
</tbody>
</table>

*An application for Associate Membership may accompany this form, but these should be submitted well before the March 1 deadline, as review of the Associate Membership application may delay registration.

*Students must enclose a statement, signed by the registrar, dean, or department head of their university or college on official letterhead, confirming their status. Postdoctoral fellows or physicians in training do not qualify for the student registration rate.

*AACR members with paid-up subscriptions to an AACR journal and registrants who pay the nonmember fee receive the Proceedings automatically. If these members or nonmembers check this box and pay the fee, they will receive an additional copy of the Proceedings.

*Optional payment for registrants outside of the U.S. and Canada only. Registrants paying this surcharge will receive meeting publications via airmail–printed matter before the annual meeting. This service not available after March 1.

AACR members in good standing will receive copies of the Program and Proceedings prior to the meeting. Nonmember and student registrants who meet the March 1 deadline will also receive the Program and (if they have purchased it) the Proceedings prior to the meeting. Nonmembers and students who do not meet the deadline must pick up publications at the meeting site.

---

**REFUND POLICY**

Refunds on registration fees will be granted on written request received in the AACR Office by April 17, 1996. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of $35 will be deducted from all refunds to cover administrative costs.

(This form may be reproduced.)
NOVEMBER 17-21, 1995  
*Novel Strategies Against Resistant Cancers*  
Chairpersons: Victor Ling, Vancouver, B.C., Canada; Daniel D. Von Hoff, San Antonio, TX  
Sanibel Harbour Resort & Spa, Ft. Myers, FL

DECEMBER 2-6, 1995  
*The Molecular Basis of Gene Transcription*  
Chairperson: Tom Curran, Memphis, TN  
Hotel Del Coronado, San Diego, CA

JANUARY 17-20, 1996  
*Cancer and the Cell Cycle*  
Joint Meeting with the Swiss Institute for Experimental Cancer Research  
Chairpersons: Edward E. Harlow, Charlestown, MA; Viesturs Simanis, Lausanne, Switzerland  
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

FEBRUARY 19-25, 1996  
*Cancer Susceptibility Genes and Molecular Carcinogenesis*  
Chairpersons: Curtis C. Harris, Bethesda, MD; Allan Balmain, Glasgow, Scotland; Kenneth Olden, Research Triangle Park, NC  
Keystone Resort, Keystone, CO

MARCH 1-5, 1996  
*Proteases and Protease Inhibitors in Cancer*  
Chairpersons: Lynn M. Matrisian, Nashville, TN; Bonnie F. Sloane, Detroit, MI  
Marriott's Bay Point Resort, Panama City Beach, FL

APRIL 20-24, 1996  
*87th Annual Meeting*  
Chairperson: Lorraine J. Gudas, New York, NY  
Washington D.C. Convention Center, Washington, D.C.  
*Abstract Deadline: December 1, 1995*

JUNE 8-12, 1996  
*Inducible Genomic Responses*  
Chairpersons: William T. Beck, Memphis, TN; John A. Hickman, Birmingham, England; Richard I. Morimoto, Evanston, IL  
Skamania Lodge, Stevenson (Columbia River Gorge), WA

OCTOBER 2-6, 1996  
*Novel Approaches in Blood and Marrow Transplantation*  
Second Annual Meeting of the American Society for Blood and Marrow Transplantation  
Chairpersons: O. Michael Colvin, Baltimore, MD; Bruce R. Blazar, Minneapolis, MN  
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996  
*Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention*  
Joint Meeting with International Agency for Research on Cancer  
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France  
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996  
*Programmed Cell Death*  
Chairperson: Stanley J. Korsmeyer, St. Louis, MO  
The Sagamore, Bolton Landing (Lake George), NY

NOVEMBER 16-20, 1996  
*Disrupted Transcription Factors in Cancer*  
Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA  
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997  
*Growth Factors and Cancer*  
Joint Meeting with Lorne Cancer Congress  
Chairpersons: Antony Burgess, Parkville, Victoria, Australia; Robert S. Coffey, Nashville, TN; Ashley R. Dunn, Parkville, Victoria, Australia; Raymond L. White, Salt Lake City, UT  
Erskine House, Lorne, Victoria, Australia

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research  
Public Ledger Building, Suite 816  
150 South Independence Mall West  
Philadelphia, PA 19106-3483  
215-440-9300 • 215-440-9313 (FAX)  
E-Mail: aacr@aol.com
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ________________________________
Name of computer used (e.g., IBM/PS2): __________________________
Operating system and version (e.g., DOS 3.3): ______________________
Word processing program and version (e.g., WordPerfect 5.0): ______
[See reverse for acceptable programs.]

Manuscript number: ________________________________
First author: _____________________________________________
Corresponding author (If different from first author): ______________
Telephone/FAX numbers: ________________________________

This form (both sides) may be reproduced.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Novel Strategies Against Resistant Cancers

November 17-21, 1995
Sanibel Harbour Resort and Spa
Ft. Myers, Florida

CONFERENCE CHAIRPERSONS
Daniel D. Von Hoff / San Antonio, TX
Victor Ling / Vancouver, British Columbia, Canada

PROGRAM COMMITTEE

Donald S. Coffey / Baltimore, MD
Eva Y. Lee / San Antonio, TX
Gertrude B. Elion / Research Triangle Park, NC
Allen I. Oliff / West Point, PA
Alexander W. Wood / Nutley, NJ
Adrian L. Harris / Oxford, England
Jeffrey M. Trent / Bethesda, MD

SCIENTIFIC PROGRAM

Keynote Address
Donald S. Coffey / Baltimore, MD

Recently Described Targets
Telomeres and Telomerase
Bradford E. Windle / San Antonio, TX
Jerry W. Shay / Dallas, TX

Farnesyl Transferase
Allen I. Oliff / West Point, PA
Alexander W. Wood / Nutley, NJ

Blood Vessels and Microenvironment
Angiogenesis
Adrian L. Harris / Oxford, England
S. Gail Eckhardt / San Antonio, TX

Strategies with Previously Described Targets
Topoisomerase I Inhibitor
Yves G. Pommier / Bethesda, MD
Mace L. Rothenberg / San Antonio, TX

Thymidylate Synthase
Youcef M. Rustum / Buffalo, NY
Neil J. Clendeninn / San Diego, CA
James L. Abbruzzese / Houston, TX

It's A Matter of Timing
William J.M. Hrushesky / Albany, NY

Biology and Clinical Trials In Resistance
Multidrug Resistance Proteins
Piet Borst / Amsterdam, The Netherlands
Susan P.C. Cole / Kingston, Ontario, Canada
Kenneth D. Tew / Philadelphia, PA

Reversing Drug Resistance
William S. Dalton / Tucson, AZ
Branimir I. Sikic / Stanford, CA

Gene Manipulating Strategies
Glenn Dranoff / Cambridge, MA
Eva Y. Lee / San Antonio, TX

Summary
Victor Ling / Vancouver, British Columbia, Canada
Daniel D. Von Hoff / San Antonio, TX

Additional Speakers to be Announced
Applicants are encouraged to submit abstracts for poster presentation. Selected proffered papers will also be scheduled for oral presentations.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300  215-440-9313 (FAX)
Priority reading for over 50 years - cited more than any other journal in its field

**CANCER RESEARCH**
Vol. 56, 1996 (24 issues)
ISSN 0008-5472

*Editor-in-Chief:
Carlo M. Croce, M.D.*

- State-of-the-art laboratory and clinical investigations
- Advances in Brief
- Selected review articles
- *Proceedings of the American Association for Cancer Research:* annual issue of research abstracts

Individual nonmembers: $460; Outside U.S.: $550
Institutions: $595*; Outside U.S.: $725*
*Includes a subscription to *Clinical Cancer Research* Available as a combined subscription only.

**A major resource on the molecular biology of cancer**

**CELL GROWTH & DIFFERENTIATION**
Vol. 7, 1996 (12 issues)
ISSN 1044-9523

*Editor-in-Chief:
George F. Vande Woude, Ph.D.*

- Original *in vitro* and *in vivo* studies of the molecular biology of cancer, including normal and abnormal cellular processes
- Research Capsules
- Viewpoints

Individual nonmembers: $95
Outside U.S.: $135
Institutions: $245; Outside U.S.: $285

**An up-to-the-minute journal spanning three vital fields**

**CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION**
Vol. 5, 1996 (12 issues)
ISSN 1055-9965

*Editor-in-Chief:
Pelayo Correa, M.D.*

- Original research on causes and prevention of cancer in humans
- Invited editorials
- Selected review articles
- Short communications
- Meeting reports

Individual nonmembers: $85
Outside U.S.: $125
Institutions: $215; Outside U.S.: $255

**An exciting new forum for clinical and translational cancer research**

**CLINICAL CANCER RESEARCH**
Vol. 2, 1996 (12 issues)
ISSN 1078-0432

*Editor-in-Chief:
John Mendelsohn, M.D.*

- Research articles
- Advances in Brief
- Minireviews
- Controversies in Clinical Cancer Research

Individual nonmembers: $95
Outside U.S.: $135
Institutions: $595*; Outside U.S.: $725*  
*Includes a subscription to *Cancer Research.* Available as a combined subscription only.

**ORDER TODAY!**
American Association for Cancer Research  
c/o FULCO, Inc.  
P.O. Box 3000  
Denville, NJ 07834  
1-800-875-2997 or (201) 627-2427  
FAX: (201) 627-5872

Members, American Association for Cancer Research:  
For member rates, contact the AACR at: (215) 440-9300  
FAX (215) 440-9313.

Institutions: Purchase all four journals and save 15% off the total subscription price, excluding postage outside U.S. Canada: Add 7% GST to all orders. MD: Add state sales tax.